

Epigenetics

Epigenetics include any process that alters gene activity without changing the DNA sequence, and leads to modifications that can be transmitted to daughter cells. Many types of epigenetic processes have been identified—they include DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs.

Many different DNA and histone modifications have been identified to determine the epigenetic landscape. DNA methylation is mainly mediated by DNA-methyl transferase (DNMT), there are two known types of DNMT, namely DNMT1, which preserves preexisting pattern of methylation after cell replication, and DNMT3A/B, so-called “de novo” DNMT, which methylate previously unmethylated DNA. Histone modifications mainly include acetylation, methylation, phosphorylation, and ubiquitination. The acetylation of histones can be mediated by histone acetyltransferases (HATs) and histone deacetyltransferases (HDACs), while Histone demethylation is performed by two classes of histone demethylases: lysine-specific demethylase (LSD) family proteins (LSD1 and LSD2) and JmjC domaincontaining histone demethylase (JHDM). Furthermore, enzymes involved in epigenetic modifications can also be governed by miRNAs. For example, miR-34a can directly inhibit the activities of SIRT1 to regulate cholesterol homeostasis.

The accumulated evidence indicates that many genes, diseases, and environmental substances are part of the epigenetics picture. At the FDA, scientists are investigating many drugs that function through epigenetic mechanisms. Drugs that inhibit DNA methylation or histone deacetylation have been studied for the reactivation of tumor suppressor genes and repression of cancer cell growth. Epigenetic inhibitors can also work alone or in combination with other therapeutic agents.

References:

- [1] Bob Weinhold. *Environ Health Perspect.* 2006 Mar; 114(3): A160–A167.
- [2] Xu W, et al. *Genet Epigenet.* 2016 Sep 25;8:43-51.
- [3] Biswas S, et al. *Pharmacol Ther.* 2017. doi: 10.1016/j.pharmthera.2017.02.011.


Target List in Epigenetics

• AMPK	3
• Aurora Kinase	7
• DNA Methyltransferase	12
• Epigenetic Reader Domain	15
• HDAC	27
• Histone Acetyltransferase	36
• Histone Demethylase	40
• Histone Methyltransferase	45
• JAK	54
• MicroRNA	62
• PARP	64
• PKC	69
• Protein Arginine Deiminase	73
• Sirtuin	75

AMPK

AMP-activated protein kinase

HDAC Inhibitor:
Vorinostat (SAHA)













HDAC (Histone deacetylase)

(GLUT4) and mitochondria.

AMPK (AMP-activated protein kinase) is an enzyme that plays a role in cellular energy homeostasis. It consists of three proteins (subunits) that together make a functional enzyme. The net effect of AMPK activation is stimulation of hepatic fatty acid oxidation and ketogenesis, inhibition of cholesterol synthesis, lipogenesis, and triglyceride synthesis, inhibition of adipocyte lipolysis and lipogenesis, stimulation of skeletal muscle fatty acid oxidation and muscle glucose uptake, and modulation of insulin secretion by pancreatic beta-cells. AMPK acts as a metabolic master switch regulating several intracellular systems including the cellular uptake of glucose, the β -oxidation of fatty acids and the biogenesis of glucose transporter 4

AMPK Inhibitors & Modulators

<p>7-Methoxyisoflavone</p> <p style="text-align: right;">Cat. No.: HY-N6631</p> <p>Bioactivity: 7-Methoxyisoflavone is an isoflavone derivative and also an activator of adenosine monophosphate-activated protein kinase (AMPK).</p> <p>Purity: 99.81%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 100 mg</p> 	<p>A-769662</p> <p style="text-align: right;">Cat. No.: HY-50662</p> <p>Bioactivity: A-769662 is a potent, reversible AMPK activator with EC₅₀ of 0.8 μM, and has little effect on GPPase/FBPase activity.</p> <p>Purity: 98.09%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>AICAR (Acadesine; AICA Riboside)</p> <p style="text-align: right;">Cat. No.: HY-13417</p> <p>Bioactivity: AICAR is a cell-permeable AMP-activated protein kinase (AMPK) activator.</p> <p>Purity: 99.92%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10mM x 1mL in Water, 50 mg, 100 mg, 200 mg, 500 mg</p> 	<p>AICAR phosphate (Acadesine phosphate; AICA Riboside phosphate)</p> <p style="text-align: right;">Cat. No.: HY-13417A</p> <p>Bioactivity: AICAR phosphate is an activator of AMP-activated protein kinase (AMPK), down-regulates the insulin receptor expression in HepG2 cells.</p> <p>Purity: 98.0%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10mM x 1mL in Water, 50 mg, 100 mg, 200 mg, 500 mg</p> 
<p>AMPK activator 1</p> <p style="text-align: right;">Cat. No.: HY-U00292</p> <p>Bioactivity: AMPK activator 1 is an AMPK activator extracted from patent WO2013116491A1, compound No.1-75, has an EC₅₀ of <0.1μM.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg, 20 mg</p> 	<p>Ampkinone</p> <p style="text-align: right;">Cat. No.: HY-12831</p> <p>Bioactivity: Ampkinone is an indirect AMP-activated protein kinase (AMPK) activator.</p> <p>Purity: 99.31%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg</p> 
<p>Chitosan oligosaccharide COS</p> <p style="text-align: right;">Cat. No.: HY-112108</p> <p>Bioactivity: Chitosan oligosaccharide (COS) is an oligomer of β-(14)-linked D-glucosamine. Chitosan oligosaccharide (COS) activates AMPK and inhibits inflammatory signaling pathways including NF-κB and MAPK pathways.</p> <p>Purity: 91.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 g, 5 g</p> 	<p>Danthron (Dantron; Chryszin; 1,8-Dihydroxyanthraquinone)</p> <p style="text-align: right;">Cat. No.: HY-B0923</p> <p>Bioactivity: Danthron is a natural product extracted from the traditional Chinese medicine rhubarb. Danthron functions in regulating glucose and lipid metabolism by activating AMPK.</p> <p>Purity: 98.0%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 100 mg</p> 
<p>Dorsomorphin (BML-275; Compound C)</p> <p style="text-align: right;">Cat. No.: HY-13418A</p> <p>Bioactivity: Dorsomorphin is a potent and selective AMPK inhibitor, that is competitive with ATP, with K_i=109±16 nM in the absence of AMP.</p> <p>Purity: 99.32%</p> <p>Clinical Data: Phase 1</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Dorsomorphin dihydrochloride (BML-275 dihydrochloride; Compound C dihydrochloride)</p> <p style="text-align: right;">Cat. No.: HY-13418</p> <p>Bioactivity: Dorsomorphin dihydrochloride (BML-275 dihydrochloride) is a potent, selective and ATP-competitive AMPK inhibitor, with a K_i of 109±16 nM.</p> <p>Purity: 99.73%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg</p> 

ETC-1002 (ESP-55016; Bempedoic acid)	Cat. No.: HY-12357
Bioactivity: ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK).	
Purity: 98.0%	
Clinical Data: Phase 3	
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	

Flufenamic acid	Cat. No.: HY-B1221
Bioactivity: Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (COX), activates AMPK , and also modulates ion channels, blocking chloride channels and L-type Ca²⁺ channels , modulating non-selective cation channel...	
Purity: 99.92%	
Clinical Data: Launched	
Size: 10mM x 1mL in DMSO, 100 mg	

Ginkgolide C (BN-52022; Ginkgolide-C)	Cat. No.: HY-N0785
Bioactivity: Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease.	
Purity: 98.0%	
Clinical Data: No Development Reported	
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg	

HTH-01-015	Cat. No.: HY-12334
Bioactivity: HTH-01-015 is a selective NUAK1 inhibitor (IC₅₀ is 100 nM). HTH-01-015 inhibits NUAK1 with >100-fold higher potency than NUAK2 (IC ₅₀ of >10 μM).	
Purity: 98.81%	
Clinical Data: No Development Reported	
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	

Metformin hydrochloride (1,1-Dimethylbiguanide hydrochloride)	Cat. No.: HY-17471A
Bioactivity: Metformin (hydrochloride) is an FDA approved first-line drug for the treatment of type 2 diabetes. Metformin decreases hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory-chain complex 1.	
Purity: 99.98%	
Clinical Data: Launched	
Size: 10mM x 1mL in Water, 10 g, 50 g	








MK-3903	Cat. No.: HY-107988
Bioactivity: MK-3903 is a potent and selective AMP-activated protein kinase (AMPK) activator with an EC₅₀ of 8 nM.	
Purity: 98.10%	
Clinical Data: No Development Reported	
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	

MK8722	Cat. No.: HY-111363
Bioactivity: MK8722 is a potent and systemic pan-AMPK activator.	
Purity: >98%	
Clinical Data: No Development Reported	
Size: 250 mg, 500 mg	

O-304	Cat. No.: HY-112233
Bioactivity: O-304 is a small molecule AMPK activator.	
Purity: 98.63%	
Clinical Data: No Development Reported	
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	


Palmitelaic Acid (9-trans-Hexadecenoic acid; trans-Palmitoleic acid)	Cat. No.: HY-N2341
Bioactivity: Palmitelaic acid is the trans isomer of palmitoleic acid. Palmitoleic acid is one of the most abundant fatty acids in serum and tissue.	
Purity: 98.00%	
Clinical Data: No Development Reported	
Size: 10mM x 1mL in Ethanol, 10 mg	

PF-06409577	Cat. No.: HY-103683
Bioactivity: PF-06409577 is a potent and selective allosteric activator of AMPK α1β1γ1 isoform with an EC₅₀ of 7 nM.	
Purity: 98.56%	
Clinical Data: Phase 1	
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	



Aurora Kinase

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)

Aurora kinases are serine/threonine kinases that are essential for cell proliferation. Aurora kinase helps the dividing cell dispense its genetic materials to its daughter cells. More specifically, Aurora kinases play a crucial role in cellular division by controlling chromatid segregation. Defects in this segregation can cause genetic instability, a condition which is highly associated with tumorigenesis. Three Aurora kinases have been identified in mammalian cells to date, Aurora A, Aurora B, Aurora C. Besides being implicated as mitotic regulators, these three kinases have generated significant interest in the cancer research field due to their elevated expression profiles in many human cancers. The human Aurora kinases present a similar domain organization, with a N-terminal domain of 39 to 129 residues in length, a protein kinase domain and a short C-terminal domain containing 15 to 20 residues. The N-terminal domain of three proteins share low sequence conservation, which determines selectivity during protein-protein interactions.

Aurora Kinase Inhibitors & Modulators

<p>ABT-348 (Ilorasertib) Cat. No.: HY-16018</p> <p>Bioactivity: ABT-348 is an ATP-competitive multitargeted kinase inhibitor with IC₅₀s for inhibiting binding Aurora B (7 nM), C (1 nM), and A (120 nM), and also inhibits RET tyrosine kinase, PDGFRβ, and Flt1 with IC₅₀s of 7 nM, 3 nM and 32 nM.</p> <p>Purity: >98% Clinical Data: Phase 2 Size: 1 mg, 5 mg, 10 mg, 20 mg</p> 	<p>Alisertib (MLN 8237) Cat. No.: HY-10971</p> <p>Bioactivity: Alisertib (MLN 8237) is a selective Aurora A inhibitor with an IC₅₀ of 1.2 nM.</p> <p>Purity: 99.43% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 
<p>AMG 900 Cat. No.: HY-13253</p> <p>Bioactivity: AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor with IC₅₀ of 5 nM, 4 nM and 1 nM for Aurora A, B and C, respectively.</p> <p>Purity: 98.19% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>AT9283 Cat. No.: HY-50514</p> <p>Bioactivity: AT9283 is a multi-targeted inhibitor with IC₅₀s of 1.2 nM, 1.1 nM for JAK2 and JAK3, respectively, and is also potent to Aurora A, Aurora B and Abl(T315I).</p> <p>Purity: 99.13% Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Aurora A inhibitor I Cat. No.: HY-70061</p> <p>Bioactivity: Aurora A inhibitor I is a potent and highly selective Aurora A inhibitor with with an IC₅₀ of 3.4 nM.</p> <p>Purity: 98.74% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Aurora B inhibitor 1 Cat. No.: HY-U00304</p> <p>Bioactivity: Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a K_i value of <0.010 μM.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 20 mg</p> 
<p>AZD1152 (Barasertib) Cat. No.: HY-10127</p> <p>Bioactivity: AZD1152 is a pro-drug of Barasertib-hQPA, which is a highly selective Aurora B inhibitor with IC₅₀ of 0.37 nM in a cell-free assay.</p> <p>Purity: 98.95% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>Barasertib-HQPA (AZD2811; INH-34; AZD1152-HQPA) Cat. No.: HY-10126</p> <p>Bioactivity: AZD1152-HQPA is a highly selective Aurora B inhibitor with IC₅₀ of 0.37 nM in a cell-free assay, and appr 3700 fold more selective for Aurora B over Aurora A.</p> <p>Purity: 99.64% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>BI-847325 Cat. No.: HY-18955</p> <p>Bioactivity: BI-847325 is an ATP competitive dual inhibitor of MEK and aurora kinases (AK) with IC₅₀ values of 4 and 15 nM for human MEK2 and AK-C, respectively.</p> <p>Purity: 98.42% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>CCT 137690 Cat. No.: HY-10804</p> <p>Bioactivity: CCT 137690 is a potent and orally available aurora kinase inhibitor with IC₅₀s of 15, 25, and 19 nM for aurora A, B and C, respectively.</p> <p>Purity: 98.33% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 

<p>CCT129202</p> <p style="text-align: right;">Cat. No.: HY-12049</p> <p>Bioactivity: CCT 137690 is an aurora kinase inhibitor with IC₅₀s of 42, 198, and 227 nM for aurora A, B and C, respectively.</p> <p>Purity: 95.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>CCT241736</p> <p style="text-align: right;">Cat. No.: HY-18161</p> <p>Bioactivity: CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants includ...</p> <p>Purity: 99.86%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>CYC-116</p> <p style="text-align: right;">Cat. No.: HY-10558</p> <p>Bioactivity: CYC-116 is a potent aurora A and aurora B inhibitor with K_is of 8 and 9 nM, respectively.</p> <p>Purity: 98.17%</p> <p>Clinical Data: Phase 1</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 	<p>Danusertib (PHA-739358)</p> <p style="text-align: right;">Cat. No.: HY-10179</p> <p>Bioactivity: Danusertib is a pyrrolo-pyrazole and aurora kinase inhibitor with IC₅₀ of 13, 79, and 61 nM for Aurora A, B, and C, respectively.</p> <p>Purity: 99.44%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>ENMD-2076</p> <p style="text-align: right;">Cat. No.: HY-10987A</p> <p>Bioactivity: ENMD-2076 is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, FIt3, KDR/VEGFR2, FIt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.</p> <p>Purity: 99.23%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>ENMD-2076 Tartrate</p> <p style="text-align: right;">Cat. No.: HY-10987</p> <p>Bioactivity: ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, FIt3, KDR/VEGFR2, FIt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.</p> <p>Purity: 98.59%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>GSK-1070916 (GSK-1070916A)</p> <p style="text-align: right;">Cat. No.: HY-70044</p> <p>Bioactivity: GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with K_is of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.</p> <p>Purity: 99.55%</p> <p>Clinical Data: Phase 1</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>Hesperadin</p> <p style="text-align: right;">Cat. No.: HY-12054</p> <p>Bioactivity: Hesperadin is an ATP-competitive inhibitor of aurora B kinase with an IC₅₀ of 250 nM.</p> <p>Purity: 98.48%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>JNJ-7706621</p> <p style="text-align: right;">Cat. No.: HY-10329</p> <p>Bioactivity: JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC₅₀s of 9, 3, 11, and 15 nM for CDK1, CDK2, Aurora-A and Aurora-B, respectively.</p> <p>Purity: 98.80%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>KW-2449</p> <p style="text-align: right;">Cat. No.: HY-10339</p> <p>Bioactivity: KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABL^{T315I} and Aurora kinase with IC₅₀s of 6.6, 14, 4 and 48 nM, respectively.</p> <p>Purity: 99.85%</p> <p>Clinical Data: Phase 1</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 

<p>MK-5108 (VX-689) Cat. No.: HY-13252</p> <p>Bioactivity: MK-5108 is a highly potent and specific inhibitor of Aurora-A kinase with an IC₅₀ value of 0.064 nM.</p> <p>Purity: 98.62% Clinical Data: Phase 1 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>MK-8745 Cat. No.: HY-13819</p> <p>Bioactivity: MK-8745 is an aurora A kinase inhibitor with IC₅₀s of 0.6 nM.</p> <p>Purity: 98.86% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 
<p>MLN8054 Cat. No.: HY-10180</p> <p>Bioactivity: MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC₅₀ of 4 nM.</p> <p>Purity: 98.0% Clinical Data: Phase 1 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>PF-03814735 Cat. No.: HY-14574</p> <p>Bioactivity: PF-03814735 is a potent, orally available and reversible aurora A and aurora B inhibitor with IC₅₀s of 0.8 and 0.5 nM, respectively.</p> <p>Purity: 99.77% Clinical Data: Phase 1 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p>PHA-680632 Cat. No.: HY-10178</p> <p>Bioactivity: PHA-680632 is an aurora kinase inhibitor with IC₅₀s of 27, 135 and 120 nM for aurora A, B and C, respectively.</p> <p>Purity: 98.02% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Reversine Cat. No.: HY-14711</p> <p>Bioactivity: Reversine is a novel class of ATP-competitive Aurora kinase inhibitor with IC₅₀s of 400, 500 and 400 nM for Aurora A, Aurora B and Aurora C, respectively.</p> <p>Purity: 99.25% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>SCH-1473759 Cat. No.: HY-10482</p> <p>Bioactivity: SCH-1473759 is an aurora inhibitor with IC₅₀s of 4 and 13 nM for aurora A and B, respectively.</p> <p>Purity: 98.20% Clinical Data: No Development Reported Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>SCH-1473759 hydrochloride Cat. No.: HY-10483</p> <p>Bioactivity: SCH-1473759 hydrochloride is an aurora inhibitor with IC₅₀s of 4 and 13 nM for aurora A and B, respectively.</p> <p>Purity: 99.67% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 
<p>SNS-314 (SNS-314 Mesylate) Cat. No.: HY-12003</p> <p>Bioactivity: SNS-314 is a potent and selective aurora kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively.</p> <p>Purity: 99.81% Clinical Data: Phase 1 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>TAK-632 Cat. No.: HY-15767</p> <p>Bioactivity: TAK-632 is a potent pan-RAF inhibitor with IC₅₀ of 1.4, 2.4 and 8.3 nM for CRAF, BRAF^{V600E}, BRAF^{WT}, respectively.</p> <p>Purity: 99.13% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 

TAK-901


Cat. No.: HY-12201

Bioactivity: TAK-901 is a multi-targeted **aurora** inhibitor with **IC₅₀s** of 21 and 15 nM for aurora A and B, respectively.

Purity: 99.80%

Clinical Data: Phase 1

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg

**Tozasertib**

(MK-0457; VX 680)


Cat. No.: HY-10161

Bioactivity: Tozasertib is the inhibitor of **Aurora A/B/C kinases** with **K_is** of 0.6, 18, 4.6 nM, respectively.

Purity: 99.77%

Clinical Data: Phase 2

Size: 10mM x 1mL in DMSO,
50 mg, 100 mg, 250 mg

**XL228**


Cat. No.: HY-15749

Bioactivity: XL228 is a multi-targeted tyrosine kinase inhibitor with **IC₅₀s** of 5, 3.1, 1.6, 6.1, 2 nM for **Bcr-Abl, Aurora A, IGF-1R, Src** and **Lyn**, respectively.

Purity: 99.58%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg

**ZM-447439**


Cat. No.: HY-10128

Bioactivity: ZM-447439 is an **aurora** kinase inhibitor with **IC₅₀s** of 110 and 130 nM for aurora A and B, respectively.

Purity: 98.59%

Clinical Data: No Development Reported


Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



DNA Methyltransferase

DNMTs; DNA MTases

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)

DNA methylation, defined by the addition of a methyl group to adenine or cytosine bases in DNA catalyzed by DNA methyltransferases (MTases), is one of the most studied post-replicative DNA modification mechanism in bacteria. The three forms of nucleotide methylation identified to date are: N6-methyladenine (^m6A), N4-methylcytosine (^m4C), and 5-methylcytosine (^m5C).

DNA methylation, one type of epigenetic modification, represses gene expression. DNA methylation is caused primarily by a family of DNA methyltransferases (DNMTs) including DNMT1, DNMT3a and DNMT3b. Conventionally, DNMT1 acts as the primary maintenance methyltransferase to keep the methylation of DNA that is already established at the genome, whereas DNMT3a and DNMT3b are classified as de novo methyltransferases to reversibly methylate unmethylated DNA. DNA methylation represses gene transcription through several mechanisms including physically blocking the binding of transcription factors and/or functioning as docking sites for transcriptional repressors/corepressors.

In epigenetic transcriptional regulation, which is important for embryonic development, DNA-methylation patterns are determined by de novo methylation by the DNA methyltransferases Dnmt3a and Dnmt3b in the embryo.

DNA methylation on the cytosine of CpG dinucleotides in gene promoter regions is associated with silencing gene expression. Of the DNA methyltransferases, only DNA methyltransferase 3a (DNMT3a) and 3b (DNMT3b) are capable of adding de novo CpG methylation marks and thus may dynamically regulate gene silencing.

DNA Methyltransferase Inhibitors & Modulators


5-Azacytidine

(Ladacamycin; 5-AzaC; Azacitidine)

Cat. No.: HY-10586

Bioactivity: 5-Azacytidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping **DNA methyltransferases**.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
 100 mg, 200 mg, 500 mg




DC-05

Cat. No.: HY-12746

Bioactivity: DC-05 is a DNA methyltransferase 1 (**DNMT1**) inhibitor, with an **IC₅₀** and a **K_d** of 10.3 μM and 1.09 μM, respectively.

Purity: 99.15%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg



DC_517

Cat. No.: HY-12747

Bioactivity: DC_517 is a DNA methyltransferase 1 (**DNMT1**) inhibitor, with an **IC₅₀** and a **K_d** of 1.7 μM and 0.91 μM, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg



Decitabine

(NSC 127716; 5-Aza-2'-deoxycytidine)

Cat. No.: HY-A0004

Bioactivity: Decitabine (NSC 127716) is a **DNA methyltransferase** inhibitor commonly used to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
 10 mg, 50 mg, 100 mg



Glucose-conjugated MGMT inhibitor

(O6BTG-C8-βGlu)

Cat. No.: HY-13057

Bioactivity: Glucose-conjugated MGMT inhibitor is a potent O⁶-methylguanine-DNA methyl-transferase (**MGMT**) inhibitor, with **IC₅₀**s of 32 nM in vitro (cell extracts) and 10 nM in HeLa S3 cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg



Guadecitabine sodium

(SGI-110 sodiums-110 sodium)

Cat. No.: HY-15229

Bioactivity: S-110 is a dinucleotide consisting of 5-Aza-CdR followed by a deoxyguanosine which shows to be an effective **DNA methylation inhibitor**.

Purity: 98.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Hinokitiol

(β-Thujaplicin)

Cat. No.: HY-B2230

Bioactivity: Hinokitiol is a component of essential oils isolated from *Chymacyparis obtusa*, reduces **Nrf2** expression, and decreases **DNMT1** and UHRF1 mRNA and protein expression, with anti-infective, anti-oxidative, and anti-tumor activities.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 50 mg, 100 mg




Lomeguatrib

(PaTrin-2)

Cat. No.: HY-13668

Bioactivity: Lomeguatrib is a O⁶-methylguanine-DNA methyltransferase (**MGMT**) inhibitor, with **IC₅₀**s of 9 nM in cell-free assay and 6nM in MCF-7 cells.

Purity: 97.95%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 10 mg, 50 mg




RG108

(N-Phthalyl-L-tryptophan)

Cat. No.: HY-13642

Bioactivity: RG108 is a non-nucleoside inhibitor of **DNA methyltransferase** with an **IC₅₀** of 115 nM.

Purity: 99.75%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 10 mg, 50 mg



SGI-1027

Cat. No.: HY-13962

Bioactivity: SGI-1027 is a **DNA methyltransferase (DNMT)** inhibitor, with **IC₅₀**s of 7.5 μM, 8 μM, and 12.5 μM for DNMT3B, DNMT3A, and DNMT1 with poly(dI-dC) as substrate.

Purity: 99.77%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 10 mg, 50 mg



SGI-110

(Guadecitabine)


Cat. No.: HY-13542

Bioactivity: SGI-110 is a **DNA methyltransferases (DNMT)** inhibitor.

Purity: 98.00%

Clinical Data: Phase 3

Size: 5 mg, 10 mg



Zebularine

(NSC309132; 4-Deoxyuridine)


Cat. No.: HY-13420

Bioactivity: Zebularine (NSC309132; 4-Deoxyuridine) is a **DNA methyltransferase** inhibitor; also an inhibitor of **cytidine deaminase** with a K_i of 0.95 μM .

Purity: 99.92%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



γ -Oryzanol


Cat. No.: HY-B2194

Bioactivity: γ -Oryzanol is a potent **DNA methyltransferases (DNMTs)** inhibitor in the striatum of mice. γ -Oryzanol significantly inhibits the activities of **DNMT1** (IC_{50} =3.2 μM), **DNMT3a** (IC_{50} =22.3 μM).

Purity: 95.0%


Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
1 g



Epigenetic Reader Domain

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)




Epigenetic regulators of gene expression and chromatin state include so-called writers, erasers, and readers of chromatin modifications. Well-characterized examples of reader domains include bromodomains typically binding acetyllysine and chromatin organization modifier (chromo), malignant brain tumor (MBT), plant homeodomain (PHD), and Tudor domains generally associating with methyllysine. Research on epigenetic readers has been tremendously influenced by the discovery of selective inhibitors targeting the bromodomain and extraterminal motif (BET) family of acetyl-lysine readers. The human genome encodes 46 proteins containing 61 bromodomains clustered into eight families. Distinct experimental

approaches are used to identify the first BET inhibitors, GSK 525762A and (+)-JQ-1.




The Polycomb group (PcG) protein, enhancer of zeste homologue 2 (EZH2), has an essential role in promoting histone H3 lysine 27 trimethylation (H3K27me3) and epigenetic gene silencing. This function of EZH2 is important for cell proliferation and inhibition of cell differentiation, and is implicated in cancer progression. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. In many types of cancers including lymphomas and leukemia, EZH2 is postulated to exert its oncogenic effects via aberrant histone and DNA methylation, causing silencing of tumor suppressor genes.

p300/CBP is not only a transcriptional adaptor but also a histone acetyltransferase.

Epigenetic Reader Domain Inhibitors & Modulators

<p>(+)-JQ-1 (JQ1) Cat. No.: HY-13030</p> <p>Bioactivity: (+)-JQ-1 is a BET bromodomain inhibitor, with IC₅₀s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2)).</p> <p>Purity: 99.90% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 5 g</p> 	<p>(+)-JQ1 PA Cat. No.: HY-112789</p> <p>Bioactivity: (+)-JQ1 PA is a derivative of the Bromodomain and extra-terminal (BET) inhibitor JQ1, with an IC₅₀ of 10.4 nM.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>(R)-(-)-JQ1 Enantiomer Cat. No.: HY-13030A</p> <p>Bioactivity: (-)-JQ-1 is the stereoisomer of (+)-JQ1. (+)-JQ1 potently decreases expression of both BRD4 target genes, whereas (-)-JQ1 has no effect.</p> <p>Purity: 99.61% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>3-Deazaneplanocin A hydrochloride (DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride) Cat. No.: HY-12186</p> <p>Bioactivity: 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor.</p> <p>Purity: 99.76% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 25 mg</p> 
<p>666-15 Cat. No.: HY-101120</p> <p>Bioactivity: 666-15 is a potent and selective CREB inhibitor with an IC₅₀ of 81 nM.</p> <p>Purity: 98.65% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>A-485 Cat. No.: HY-107455</p> <p>Bioactivity: A-485 is a potent and selective catalytic inhibitor of p300/CBP with IC₅₀s of 9.8nM and 2.6nM for p300 and CBP, respectively.</p> <p>Purity: 99.08% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>ABBV-744 Cat. No.: HY-112090</p> <p>Bioactivity: ABBV-744 is a highly BDII-selective BET bromodomain inhibitor, used in the research of inflammatory diseases, cancer, and AIDS.</p> <p>Purity: 90.0% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>Anacardic Acid (Hydroginkgolic acid) Cat. No.: HY-N2020</p> <p>Bioactivity: Anacardic Acid, extracted from cashew nut shell liquid, is a histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC₅₀s of 8.5 μM and 5 μM, respectively.</p> <p>Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg</p> 
<p>ARV-771 Cat. No.: HY-100972</p> <p>Bioactivity: ARV-771 is a potent bromodomain and extra-terminal (BET) proteins degrader based on PROTAC technology with K_d values of 4.7, 7.6, 7.6 nM against BRD2, BRD3 and BRD4, respectively.</p> <p>Purity: 99.44% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>ARV-825 Cat. No.: HY-16954</p> <p>Bioactivity: ARV-825 is a BRD4 Inhibitor based on PROTAC technology. ARV-825 binds to BD1 and BD2 of BRD4 with K_ds of 90 and 28 nM, respectively.</p> <p>Purity: 99.37% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 





<p>AZD5153 6-Hydroxy-2-naphthoic acid (AZD-5153 HNT salt) Cat. No.: HY-100653A</p> <p>Bioactivity: AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC₅₀ of 1.7 nM.</p> <p>Purity: 98.05% Clinical Data: Phase 1 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>BAY-299 Cat. No.: HY-107424</p> <p>Bioactivity: BAY-299 is a very potent, dual inhibitor with IC₅₀s of 67 nM for BRPF2 bromodomains (BD), 8 nM for TAF1 BD2, and 106 nM for TAF1L BD2.</p> <p>Purity: 99.24% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>BET bromodomain inhibitor Cat. No.: HY-103036</p> <p>Bioactivity: BET bromodomain inhibitor is a potent BET inhibitor extracted from patent WO/2015/153871A2, compound example 11.</p> <p>Purity: 99.51% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>BET-BAY 002 Cat. No.: HY-12421</p> <p>Bioactivity: BET-BAY 002 is a potent BET inhibitor; shows efficacy in a multiple myeloma model.</p> <p>Purity: 99.52% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>BET-BAY 002 S enantiomer Cat. No.: HY-12421B</p> <p>Bioactivity: BET-BAY 002 S enantiomer is the S-enantiomer of BET-BAY 002. BET-BAY 002 is a BET inhibitor.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg</p> 	<p>BET-IN-1 Cat. No.: HY-19760</p> <p>Bioactivity: BET-IN-1 is a bromodomain inhibitor extracted from patent WO/2013024104A1, compound example 2, has a pIC₅₀ in the range 6.0 - 7.0.</p> <p>Purity: 99.01% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>BETd-260 (ZBC 260; ZBC-260; BETd260) Cat. No.: HY-101519</p> <p>Bioactivity: BETd-260 is a potent BET degrader based on PROTAC technology, with an IC₅₀ of 30 pM against BRD4 protein in RS4;11 leukemia cell line.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>BI 2536 Cat. No.: HY-50698</p> <p>Bioactivity: BI 2536 is a dual PLK1 and BRD4 inhibitor with IC₅₀s of 0.83 and 25 nM, respectively.</p> <p>Purity: 99.95% Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>BI-7273 Cat. No.: HY-100351</p> <p>Bioactivity: BI-7273 is a selective, and cell-permeable BRD9 inhibitor, with an IC₅₀ and a K_d of 19 and 0.75 nM; also shows high effect on BRD7, with an IC₅₀ and a K_d of 117 nM and 0.3 nM.</p> <p>Purity: 99.65% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>BI-9564 Cat. No.: HY-100352</p> <p>Bioactivity: BI-9564 is a selective, and cell-permeable BRD9 BD inhibitor, with K_d of 5.9 nM for BRD9, and IC₅₀ of > 100 μM for BET family.</p> <p>Purity: 99.55% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 

<p>BMS-986158</p> <p style="text-align: right;">Cat. No.: HY-101567</p> <p>Bioactivity: BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins.</p> <p>Purity: 98.03%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>BRD4 degrader AT1</p> <p style="text-align: right;">Cat. No.: HY-111433</p> <p>Bioactivity: BRD4 degrader AT1 is a highly selective Brd4 degrader based on PROTAC technology, with a K_d of 44 nM for Brd4^{BD2} in cells.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg</p> 
<p>Bromosporine</p> <p style="text-align: right;">Cat. No.: HY-15815</p> <p>Bioactivity: Bromosporine is a broad spectrum inhibitor for bromodomains with IC₅₀ of 0.41 μM, 0.29 μM, 0.122 μM and 0.017 μM for BRD2, BRD4, BRD9 and CECR2, respectively.</p> <p>Purity: 99.36%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>C646</p> <p style="text-align: right;">Cat. No.: HY-13823</p> <p>Bioactivity: C646 is a selective and competitive histone acetyltransferase p300 inhibitor with K_i of 400 nM, and is less potent for other acetyltransferases.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 
<p>CeMMEC1</p> <p style="text-align: right;">Cat. No.: HY-111445</p> <p>Bioactivity: CeMMEC1 is an inhibitor of BRD4, and also has high affinity for TAF1, with an IC₅₀ of 0.9 μM for TAF1, and a K_d of 1.8 μM for TAF1 (2).</p> <p>Purity: 98.03%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>CPI-169 (CPI 169 R-enantiomer)</p> <p style="text-align: right;">Cat. No.: HY-15956A</p> <p>Bioactivity: CPI-169 is a novel and potent EZH2 inhibitor, with IC₅₀s of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.</p> <p>Purity: 96.99%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>CPI-169 racemate</p> <p style="text-align: right;">Cat. No.: HY-15956</p> <p>Bioactivity: CPI-169 racemate is the racemate of CPI-169. CPI-169 is a novel and potent EZH2 inhibitor.</p> <p>Purity: 96.73%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>CPI-203</p> <p style="text-align: right;">Cat. No.: HY-15846</p> <p>Bioactivity: CPI-203 is a novel potent, selective and cell permeable inhibitor of BET bromodomain, with an IC₅₀ value of approx 37 nM (BRD4 α-screen assay).</p> <p>Purity: 99.38%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg</p> 
<p>CPI-360</p> <p style="text-align: right;">Cat. No.: HY-15955</p> <p>Bioactivity: CPI-360 is a potent, selective EZH2 inhibitor with IC₅₀ of 0.5 nM and 2.5 nM for wt EZH2 and Y641N EZH2, respectively.</p> <p>Purity: 99.14%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>CPI-637</p> <p style="text-align: right;">Cat. No.: HY-100482</p> <p>Bioactivity: CPI-637 is a potent and selective CBP/EP300 bromodomains inhibitor with IC₅₀ of 0.03±0.01μM and 11.0±0.6 μM for CBP/EP300 and BRD4, respectively. IC₅₀:0.03±0.01μM (CBP/EP300)[1] IC₅₀:11.0±0.6 μM(BRD4)[1] CPI-637, which demonstrated substantial biochemical potency that was...</p> <p>Purity: 99.94%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 

<p>Curcumin (Indian Saffron; Turmeric yellow; Natural Yellow 3; Diferuloylmethane) Cat. No.: HY-N0005</p> <p>Bioactivity: Curcumin is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetyltransferase ((HATs)) and also shows inhibitory effects on NF-κB and...</p> <p>Purity: 99.66%</p> <p>Clinical Data: Phase 4</p> <p>Size: 10mM x 1mL in DMSO, 100 mg, 500 mg</p> 	<p>dBET1 Cat. No.: HY-101838</p> <p>Bioactivity: dBET1 is a potent BRD4 protein degrader based on PROTAC technology with an EC₅₀ of 430 nM.</p> <p>Purity: 99.24%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>dBET6 Cat. No.: HY-112588</p> <p>Bioactivity: dBET6 is a highly potent, selective and cell-permeable degrader of BET with an IC₅₀ of 14 nM, and has antitumor activity.</p> <p>Purity: 99.40%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>dTRIM24 Cat. No.: HY-111519</p> <p>Bioactivity: dTRIM24 is a selective bifunctional degrader of TRIM24.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>DZNep (3-Deazaneplanocin A; 3-Deazaneplanocin) Cat. No.: HY-10442</p> <p>Bioactivity: 3-Deazaneplanocin A is a potent histone methyltransferase EZH2 inhibitor.</p> <p>Purity: 98.12%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg</p> 	<p>E-7386 Cat. No.: HY-111386</p> <p>Bioactivity: E-7386 is an orally active CBP/beta-catenin modulator.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg, 50 mg</p> 
<p>E3 Ligase Ligand-Linker Conjugates 19 Cat. No.: HY-107438</p> <p>Bioactivity: E3 Ligase Ligand-Linker Conjugates 19 is a degron-linker. The PROTAC linker is bound to at least one targeting ligand.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p> 	<p>E3 Ligase Ligand-Linker Conjugates 20 Cat. No.: HY-107439</p> <p>Bioactivity: E3 Ligase Ligand-Linker Conjugates 20 is a degron-linker (refer to Compound DL7-TL). The PROTAC linker is bound to at least one targeting ligand.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p> 
<p>E3 Ligase Ligand-Linker Conjugates 21 Cat. No.: HY-107440</p> <p>Bioactivity: E3 Ligase Ligand-Linker Conjugates 21 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p> 	<p>EBI-2511 Cat. No.: HY-111418</p> <p>Bioactivity: EBI-2511 is a highly potent and orally active EZH2 inhibitor, with an IC₅₀ of 6 nM in Pfeifferia cell lines, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p> 


<p>EED inhibitor-1</p> <p style="text-align: right;">Cat. No.: HY-103663</p> <p>Bioactivity: EED inhibitor-1 is an EED inhibitor extracted from patent US20160176882 A1, compound example 2; has IC₅₀s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay.</p> <p>Purity: 98.05%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>EI1 (Ezh2 inhibitor)</p> <p style="text-align: right;">Cat. No.: HY-15573</p> <p>Bioactivity: EI1 is a potent and selective EZH2 inhibitor with IC₅₀ of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.</p> <p>Purity: 99.74%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>EML 425</p> <p style="text-align: right;">Cat. No.: HY-110263</p> <p>Bioactivity: EML425 is a potent and selective CREB binding protein (CBP)/p300 inhibitor with IC₅₀s of 2.9 and 1.1 μM, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg</p> 	<p>EPZ-6438 (Tazemetostat; E-7438)</p> <p style="text-align: right;">Cat. No.: HY-13803</p> <p>Bioactivity: EPZ-6438 (Tazemetostat) is a potent, selective and orally available EZH2 inhibitor with K_i and IC₅₀ of 2.5 and 11 nM, respectively.</p> <p>Purity: 99.63%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 
<p>EPZ005687</p> <p style="text-align: right;">Cat. No.: HY-15555</p> <p>Bioactivity: EPZ005687 is a potent and selective inhibitor of EZH2 with K_i of 24 nM, and has 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.</p> <p>Purity: 98.97%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>EPZ011989</p> <p style="text-align: right;">Cat. No.: HY-16986</p> <p>Bioactivity: EPZ011989 is a potent, selective orally bioavailable EZH2 inhibitor with K_i < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.</p> <p>Purity: 99.36%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>EPZ011989 trifluoroacetate (EPZ-011989 trifluoroacetate)</p> <p style="text-align: right;">Cat. No.: HY-16986A</p> <p>Bioactivity: EPZ011989 trifluoroacetate is a potent, selective orally bioavailable EZH2 inhibitor with K_i < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>FL-411 (BRD4-IN-1)</p> <p style="text-align: right;">Cat. No.: HY-111102</p> <p>Bioactivity: FL-411 is a potent and selective BRD4 inhibitor with an IC₅₀ of 0.43\pm0.09 μM for BRD4(1).</p> <p>Purity: 98.02%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>GNE-049</p> <p style="text-align: right;">Cat. No.: HY-108435</p> <p>Bioactivity: GNE-049 is a highly potent and selective CBP inhibitor with an IC₅₀ of 1.1 nM in TR-FRET assay. GNE-049 also inhibits BRET and BRD4(1) with IC₅₀s of 12 nM and 4200 nM, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 mg, 250 mg</p> 	<p>GNE-272</p> <p style="text-align: right;">Cat. No.: HY-100726</p> <p>Bioactivity: GNE-272 is a potent and selective <i>in vivo</i> probe for the bromodomains of CBP/EP300 with IC₅₀ values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 


<p>GENE-781</p> <p style="text-align: right;">Cat. No.: HY-108696</p> <p>Bioactivity: GNE-781 is a highly potent and selective CBP inhibitor with an IC₅₀ of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC₅₀s of 6.2 nM and 5100 nM, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 mg, 250 mg</p> 	<p>GSK 4027</p> <p style="text-align: right;">Cat. No.: HY-101027</p> <p>Bioactivity: GSK 4027 is a chemical probe for the PCAF/ GCN5 bromodomain with an pIC₅₀ of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.</p> <p>Purity: 98.01%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>GSK 525762A (I-BET 762; Molibresib)</p> <p style="text-align: right;">Cat. No.: HY-13032</p> <p>Bioactivity: GSK 525762A is a BET bromodomain inhibitor with IC₅₀ of 32.5-42.5 nM.</p> <p>Purity: 99.85%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>GSK 525768A</p> <p style="text-align: right;">Cat. No.: HY-13032A</p> <p>Bioactivity: GSK 525768A is a bromodomain inhibitor, competitively inhibit the binding of acetylated lysine-containing peptides to bromodomains.</p> <p>Purity: 99.62%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>GSK-5959</p> <p style="text-align: right;">Cat. No.: HY-18665</p> <p>Bioactivity: GSK-5959 is a potent, selective and cell permeable BRPF1 bromodomain inhibitor with IC50 ~ 80 nM. Exhibits >100-fold selectivity for BRPF1 over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains. IC50 value: 80 nM Target: BRPF1 in vitro: GSK-5959 inhibits BRPF1 interaction...</p> <p>Purity: 98.42%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>GSK126 (EZH2 inhibitor; GSK2816126A)</p> <p style="text-align: right;">Cat. No.: HY-13470</p> <p>Bioactivity: GSK126 is a potent, highly selective inhibitor of EZH2 methyltransferase with an IC₅₀ of 9.9 nM.</p> <p>Purity: 99.86%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 
<p>GSK1324726A (I-BET726)</p> <p style="text-align: right;">Cat. No.: HY-13960</p> <p>Bioactivity: GSK1324726A is a novel, potent, and selective inhibitor of BET proteins with high affinity to BRD2 (IC₅₀=41 nM), BRD3 (IC₅₀=31 nM), and BRD4 (IC₅₀=22 nM).</p> <p>Purity: 98.21%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>GSK2801</p> <p style="text-align: right;">Cat. No.: HY-15658</p> <p>Bioactivity: GSK2801 is a potent, selective and cell active acetyl-lysine competitive inhibitor of BAZ2A(Kd=136 nM) and BAZ2B(Kd=257 nM) bromodomains. IC50 value: 136 nM/257 nM(Kd, BAZ2A/BAZ2B) [1] Target: BAZ2A/2B inhibitor GSK2801 binds to BAZ2 bromodomains with dissociation constants (KD) of 136 and 257 nM for BAZ2B...</p> <p>Purity: 99.73%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p>GSK343</p> <p style="text-align: right;">Cat. No.: HY-13500</p> <p>Bioactivity: GSK343 is a highly potent and selective EZH2 inhibitor with an IC₅₀ of 4 nM.</p> <p>Purity: 98.49%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>GSK4028</p> <p style="text-align: right;">Cat. No.: HY-101027A</p> <p>Bioactivity: GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC₅₀ of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 


<p>GSK503</p> <p style="text-align: right;">Cat. No.: HY-12856</p> <p>Bioactivity: GSK503 is a potent and specific inhibitor of EZH2 methyltransferase with K_i^{APP} values of 3 to 27 nM.</p> <p>Purity: 98.99%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>GSK6853</p> <p style="text-align: right;">Cat. No.: HY-100220</p> <p>Bioactivity: GSK6853 is a potent and selective inhibitor of the BRPF1 bromodomain. shows excellent BRPF1 potency (pKd 9.5) and greater than 1600-fold selectivity over all other bromodomains tested.</p> <p>Purity: 99.31%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>GSK9311</p> <p style="text-align: right;">Cat. No.: HY-100729</p> <p>Bioactivity: GSK9311 is a potent inhibitor of the BRPF bromodomain with pIC_{50} values of 6.0 and 4.3 for BRPF1 and BRPF2, respectively.</p> <p>Purity: 99.09%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>I-BET151 (GSK1210151A)</p> <p style="text-align: right;">Cat. No.: HY-13235</p> <p>Bioactivity: I-BET151 is a BET bromodomain inhibitor which inhibits BRD4, BRD2, and BRD3 with pIC_{50} of 6.1, 6.3, and 6.6, respectively.</p> <p>Purity: 98.77%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>I-BRD9</p> <p style="text-align: right;">Cat. No.: HY-18975</p> <p>Bioactivity: I-BRD9 is the first selective cellular chemical probe for BRD9 ($pIC_{50}=7.3$).</p> <p>Purity: 99.16%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>I-CBP112</p> <p style="text-align: right;">Cat. No.: HY-19541</p> <p>Bioactivity: I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that targets the CBP/p300 bromodomains.</p> <p>Purity: 98.57%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>IACS-9571 (ASIS-P040)</p> <p style="text-align: right;">Cat. No.: HY-102000</p> <p>Bioactivity: IACS-9571 is a potent and selective inhibitor of TRIM24 and BRPF1, with IC_{50} of 8 nM for TRIM24, and K_ds of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>IACS-9571 Hydrochloride (ASIS-P040 Hydrochloride)</p> <p style="text-align: right;">Cat. No.: HY-102000B</p> <p>Bioactivity: IACS-9571 Hydrochloride is a potent and selective inhibitor of TRIM24 and BRPF1, with an IC_{50} of 8 nM for TRIM24, and K_ds of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.</p> <p>Purity: 99.02%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>INCB-057643</p> <p style="text-align: right;">Cat. No.: HY-111485</p> <p>Bioactivity: INCB-057643 is a novel, orally bioavailable BET inhibitor.</p> <p>Purity: 98.91%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>INCB054329</p> <p style="text-align: right;">Cat. No.: HY-112504</p> <p>Bioactivity: INCB054329 is a potent BET inhibitor.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 


<p>INCB054329 Racemate</p> <p style="text-align: right;">Cat. No.: HY-112504A</p>	<p>JQ-1 carboxylic acid</p> <p style="text-align: right;">Cat. No.: HY-78695</p>
<p>Bioactivity: INCB054329 Racemate is a BET protein inhibitor.</p> <p>Purity: 96.69%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>Bioactivity: JQ-1 carboxylic acid is a highly potent, selective and cell-permeable BRD4 inhibitor with IC₅₀s of 77 nM and 33 nM for BRD4(1) and BRD4(2), respectively.</p> <p>Purity: 99.59%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 5 g</p> 
<p>JQ-35, (S)-</p> <p style="text-align: right;">Cat. No.: HY-117286</p>	<p>JQEZ5</p> <p style="text-align: right;">Cat. No.: HY-100846</p>
<p>Bioactivity: JQ-35, (S)- is an inhibitor of the BET (Bromodomain and Extra-Terminal) family bromodomain-containing proteins with potential antineoplastic activity.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Bioactivity: JQEZ5 is a novel and potent EZH2 inhibitor.</p> <p>Purity: 98.00%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>KG-501 (Naphthol AS-E phosphate)</p> <p style="text-align: right;">Cat. No.: HY-103299</p>	<p>L-45 (L-Moses)</p> <p style="text-align: right;">Cat. No.: HY-101125</p>
<p>Bioactivity: KG-501 is a CREB inhibitor, with an IC₅₀ of 6.89 μM.</p> <p>Purity: 99.12%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>Bioactivity: L-45 is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a K_d of 126\pm15 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg</p> 
<p>L-45 dihydrochloride (L-Moses dihydrochloride)</p> <p style="text-align: right;">Cat. No.: HY-101125A</p>	<p>MG 149</p> <p style="text-align: right;">Cat. No.: HY-15887</p>
<p>Bioactivity: L-45 dihydrochloride is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a K_d of 126\pm15 nM.</p> <p>Purity: 99.38%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg</p> 	<p>Bioactivity: MG149 is a selective and potent Tip60 inhibitor with IC₅₀ of 74 μM, similar potency for MOF(IC₅₀= 47 μM); little potent for PCAF and p300(IC₅₀ >200 μM). IC₅₀ value: 74/47 μM (Tip60/MOF) [1] Target: Tip60/MOF MG 149, at 200 μM, inhibited about 90% of Tip60 activity but had no inhibitory impact on...</p> <p>Purity: 99.48%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p>Mivebresib (ABBV-075)</p> <p style="text-align: right;">Cat. No.: HY-100015</p>	<p>MS417 (GTPL7512)</p> <p style="text-align: right;">Cat. No.: HY-111139</p>
<p>Bioactivity: Mivebresib is a potent and orally available bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a K_i of 1.5 nM.</p> <p>Purity: 99.28%</p> <p>Clinical Data: Phase 1</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>Bioactivity: MS417 is a BET-specific BRD4 inhibitor, binds to BRD4-BD1 and BRD4-BD2 with IC₅₀s of 30, 46 nM and K_ds of 36.1, 25.4 nM, respectively, with weak selectivity at CBP BRD (IC₅₀ 32.7 μM).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 


<p>MS436</p> <p style="text-align: right;">Cat. No.: HY-13959</p> <p>Bioactivity: MS436 is a new class of bromodomain inhibitor, exhibits potent affinity of an estimated $K_i=30-50$ nM for the BRD4 BrD1 and a 10-fold selectivity over the BrD2.</p> <p>Purity: 98.02%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>MZ 1</p> <p style="text-align: right;">Cat. No.: HY-107425</p> <p>Bioactivity: MZ 1 is a BRD4 protein degrader based on PROTAC technology.</p> <p>Purity: 99.35%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg</p> 
<p>MZP-54</p> <p style="text-align: right;">Cat. No.: HY-112376</p> <p>Bioactivity: MZP-54 is a selective degrader of BRD3/4 based on PROTAC technology, with a K_d of 4 nM for Brd4^{BD2}.</p> <p>Purity: 98.05%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg</p> 	<p>MZP-55</p> <p style="text-align: right;">Cat. No.: HY-112377</p> <p>Bioactivity: MZP-55 is a selective degrader of BRD3/4 based on PROTAC technology, with a K_d of 8 nM for Brd4^{BD2}.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg</p> 
<p>NI-57</p> <p style="text-align: right;">Cat. No.: HY-19537</p> <p>Bioactivity: NI-57 is an inhibitor of bromodomain and plant homeodomain finger-containing (BRPF) family of proteins, with IC_{50}s of 3.1, 46 and 140 nM for BRPF1, BRPF2 (BRD1) and BRPF3, respectively.</p> <p>Purity: 99.89%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>OF-1</p> <p style="text-align: right;">Cat. No.: HY-12518</p> <p>Bioactivity: OF-1 is a selective BRPF1B and BRPF2 bromodomain inhibitor with K_d values of 100 nM/500 nM for BRPF1B/BRPF2; 39-fold selectivity over BRD4.</p> <p>Purity: 98.13%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p>OTX-015 (MK-8628; Birabresib)</p> <p style="text-align: right;">Cat. No.: HY-15743</p> <p>Bioactivity: OTX-015 is a potent bromodomain (BRD2/3/4) inhibitor with IC_{50}s ranging from 92 to 112 nM.</p> <p>Purity: 99.81%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>PF-06726304</p> <p style="text-align: right;">Cat. No.: HY-103682</p> <p>Bioactivity: PF-06726304 is a potent and selective EZH2 inhibitor with a K_i of 0.7 nM.</p> <p>Purity: 98.96%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg</p> 
<p>PF-CBP1 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-19999A</p> <p>Bioactivity: PF-CBP1 hydrochloride is a highly selective inhibitor of the CREB binding protein bromodomain. Target: CREB in vitro: PF-CBP1 modulates key inflammatory genes in primary macrophages. PF-CBP1 downregulates RGS4 in neurons, a target linked to Parkinson's disease. PF-CBP1 is 139-fold selective...</p> <p>Purity: 99.77%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>PFI-1</p> <p style="text-align: right;">Cat. No.: HY-16586</p> <p>Bioactivity: PFI-1 is a selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC_{50} of 0.22 μM in a cell-free assay.</p> <p>Purity: 99.80%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 


PFI-3	Cat. No.: HY-12409
Bioactivity:	PFI-3 is a selective, potent and cell-permeable SMARCA2/4 bromodomain inhibitor with a K_d of 89 nM.
Purity:	98.06%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
	


PFI-4	Cat. No.: HY-18664
Bioactivity:	PFI-4 is a potent and selective and cell permeable BRPF1 bromodomain inhibitor (IC50 = 80 nM). Exhibits >100-fold selectivity for BRPF1 over a panel of other bromodomains including BRPF2 (BRD1), BRPF3 and BRD4.
Purity:	99.35%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
	


PLX51107	Cat. No.: HY-111422
Bioactivity:	PLX51107 is a potent and selective BET inhibitor, with K_d s of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP...
Purity:	99.81%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
	


PROTAC 11	Cat. No.: HY-103633
Bioactivity:	PROTAC 11 is a potent BET degrader based on PROTAC , decreasing BRD2, BRD3, and BRD4 protein levels at low concentration.
Purity:	>98%
Clinical Data:	No Development Reported
Size:	5 mg, 10 mg, 25 mg
	


QCA570	Cat. No.: HY-112609
Bioactivity:	QCA570 is a potent BET degrader, with an IC_{50} of 10 nM for BRD4 BD1 Protein.
Purity:	>98%
Clinical Data:	No Development Reported
Size:	250 mg, 500 mg
	

RVX-208	Cat. No.: HY-16652
(Apabetalone; RVX000222)	
Bioactivity:	RVX-208 is an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. The IC_{50} s are $87 \pm 10 \mu\text{M}$ and $0.51 \pm 0.041 \mu\text{M}$ for BD1 and BD2 , respectively.
Purity:	99.19%
Clinical Data:	Phase 3
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
	

SF2523	Cat. No.: HY-101146
Bioactivity:	SF2523 is a highly selective and potent inhibitor of PI3K with IC_{50} s of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα , PI3Kγ , DNA-PK , BRD4 and mTOR, respectively.
Purity:	99.37%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
	

SGC-CBP30	Cat. No.: HY-15826
Bioactivity:	SGC-CBP30 is a potent CREBBP/EP300 bromodomain inhibitor with IC_{50} of 21-69 and 38 nM for CREBBP and EP300 bromodomains, respectively. IC_{50} Value: 21-69 nM(for CREBBP); 38 nM(for EP300) Target: Others in vivo: SGC-CBP30 is a highly potent and selective p300/CBP bromodomain inhibitor (IC_{50} ...
Purity:	99.19%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
	

Target Protein-binding moiety 4	Cat. No.: HY-107443
Bioactivity:	Target Protein-binding moiety 4 is a BRD4 (1) inhibitor with an IC_{50} of 7.9 μM .
Purity:	96.04%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg
	

Target Protein-binding moiety 6	Cat. No.: HY-107445
Bioactivity:	Target Protein-binding moiety 6 is a compound that binds to BRD9 , and used for inhibiting BRD9 activity.
Purity:	>98%
Clinical Data:	No Development Reported
Size:	250 mg, 500 mg
	

TPOP146


Cat. No.: HY-100697

Bioactivity: TPOP146 is a selective **CBP/P300** benzoxazepine bromodomain inhibitor with K_d values of 134 nM and 5.02 μ M for CBP and BRD4.

Purity: 99.66%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg

**UNC1999**


Cat. No.: HY-15646

Bioactivity: UNC1999 is a SAM-competitive, potent and selective inhibitor of **EZH1/2** with IC_{50} s of 10 nM and 45 nM, respectively.

Purity: 99.47%


Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



HDAC

Histone deacetylases



HDAC (Histone deacetylases) are a class of enzymes that remove acetyl groups ($O=C-CH_3$) from an ϵ -N-acetyl lysine amino acid on a histone, allowing the histones to wrap the DNA more tightly. This is important because DNA is wrapped around histones, and DNA expression is regulated by acetylation and de-acetylation. Its action is opposite to that of histone acetyltransferase. HDAC proteins are now also called lysine deacetylases (KDAC), to describe their function rather than their target, which also includes non-histone proteins. Together with the acetyl polyamine amidohydrolases and the acetoacetyl utilization proteins, the histone deacetylases form an ancient protein superfamily known as the histone deacetylase superfamily.

HDAC Inhibitors & Modulators


4SC-202

(domatinostat tosylate)

Cat. No.: HY-16012

Bioactivity: 4SC-202 is a selective class I **HDAC** inhibitor with **IC₅₀** of 1.20 μ M, 1.12 μ M, and 0.57 μ M for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against **Lysine specific demethylase 1 (LSD1)**.

Purity: 98.81%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg, 100 mg



4SC-202 free base

(domatinostat)

Cat. No.: HY-16012A

Bioactivity: 4SC-202 (free base) is a selective class I **HDAC** inhibitor with **IC₅₀** of 1.20 μ M, 1.12 μ M, and 0.57 μ M for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against **Lysine specific demethylase 1 (LSD1)**.

Purity: 98.99%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg, 100 mg




ACY-1215

(Ricolinostat; Rocilinostat)

Cat. No.: HY-16026

Bioactivity: ACY-1215 is a potent and selective **HDAC6** inhibitor, with an **IC₅₀** of 5 nM. ACY-1215 also inhibits **HDAC1**, **HDAC2**, and **HDAC3** with **IC₅₀**s of 58, 48, and 51 nM, respectively.

Purity: 98.90%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg, 100 mg




ACY-738

Cat. No.: HY-19327

Bioactivity: ACY-738 is a potent, selective and orally-bioavailable **HDAC6** inhibitor, with an **IC₅₀** of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with **IC₅₀**s of 94, 128, and 218 nM.

Purity: 99.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg, 100 mg




ACY-775

Cat. No.: HY-19328

Bioactivity: ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (**HDAC6**) with an **IC₅₀** of 7.5nM.

Purity: 99.54%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg




ACY-957

Cat. No.: HY-104008

Bioactivity: ACY-957 is a selective inhibitor of **HDAC1** and **HDAC2**, with **IC₅₀**s of 7 nM, 18 nM, and 1300 nM against HDAC1/2/3, respectively, and shows no inhibition on HDAC4/5/6/7/8/9.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg




Belinostat

(PXD101; PX105684)

Cat. No.: HY-10225

Bioactivity: Belinostat is a potent **HDAC** inhibitor with an **IC₅₀** of 27 nM in HeLa cell extracts.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
 10 mg, 50 mg, 100 mg, 200 mg




BG45

Cat. No.: HY-18712

Bioactivity: BG45 is an HDAC class I inhibitor with selectivity for HDAC3 (**IC₅₀** = 289 nM). It inhibits HDAC1, HDAC2, and HDAC6 with greatly reduced potency (**IC₅₀**s = 2, 2.2, and >20 μ M, respectively). **IC₅₀** value: 289 nM (HDAC3), 2 μ M (HDAC1), 2.2 μ M (HDAC2), >20 μ M (HDAC6) Target: HDAC At concentrations...

Purity: 99.71 %
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg, 100 mg



BML-210

Cat. No.: HY-19350

Bioactivity: BML-210 is a novel HDAC inhibitor, and its mechanism of action has not been characterized. **IC₅₀** value: 5 μ M[1] Target: HDAC4
 In vitro: Cell cycle analysis indicated that HeLa cell treatment with 20 and 30 μ M concentration of BML-210 increased the proportion of cells in G0/G1 phase, and caused...

Purity: 96.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 50 mg












BRD 4354

Cat. No.: HY-112719




Bioactivity: BRD 4354 is a moderately potent inhibitor of **HDAC5** and **HDAC9**, with **IC₅₀**s of 0.85 and 1.88 μ M, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size:



<p>BRD73954</p> <p style="text-align: right;">Cat. No.: HY-18700</p> <p>Bioactivity: BRD73954 is a potent and selective HDAC inhibitor with IC₅₀ of 36 nM and 120 nM for HDAC6 and HDAC8, respectively.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>Bufexamac (Bufexamic acid)</p> <p style="text-align: right;">Cat. No.: HY-B0494</p> <p>Bioactivity: Bufexamac is a class IIB histone deacetylases (HDAC6 and HDAC10) inhibitor used as an anti-inflammatory agent.</p> <p>Purity: 98.0%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 100 mg, 500 mg</p> 
<p>CAY10603</p> <p style="text-align: right;">Cat. No.: HY-18613</p> <p>Bioactivity: CAY10603 is a potent and selective HDAC6 inhibitor, with an IC₅₀ of 2 µM; CAY10603 also inhibits HDAC1, HDAC2, HDAC3, HDAC8, HDAC10, with IC₅₀s of 271, 252, 0.42, 6851, 90.7 nM.</p> <p>Purity: 98.08%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>Chidamide (CS055; HBI-8000)</p> <p style="text-align: right;">Cat. No.: HY-13592</p> <p>Bioactivity: Chidamide is a synthetic benzamide-type HDAC inhibitor, inhibits HDAC1, HDAC2, HDAC3 and HDAC10 with IC₅₀s of 95, 160, 67 and 78 nM, respectively.</p> <p>Purity: 96.09%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg</p> 
<p>CI-994 (Acetylinaline; Tacedinaline; PD 123654; Goe 5549)</p> <p style="text-align: right;">Cat. No.: HY-50934</p> <p>Bioactivity: CI-994 (Tacedinaline) is an inhibitor of the histone deacetylase (HDAC) with IC₅₀s of 0.9, 0.9, 1.2 µM for recombinant HDAC 1, 2 and 3 respectively.</p> <p>Purity: 99.08%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</p> 	<p>Citarinostat (ACY241)</p> <p style="text-align: right;">Cat. No.: HY-15994</p> <p>Bioactivity: Citarinostat is a HDAC6 specific inhibitor, with IC₅₀ of 4 nM and 76 nM for HDAC6 and HDAC3, respectively. IC₅₀ value: 4 nM (HDAC6), 76 nM (HDAC3) Target: HDAC The detailed information please refer to WO2015061684A1 and 2015054197A1.</p> <p>Purity: 99.06%</p> <p>Clinical Data: Phase 1</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p>Corin</p> <p style="text-align: right;">Cat. No.: HY-111048</p> <p>Bioactivity: Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC), with a K_i(inact) of 110 nM for LSD1 and an IC₅₀ of 147 nM for HDAC1.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 mg, 250 mg</p> 	<p>CRA-026440</p> <p style="text-align: right;">Cat. No.: HY-19754</p> <p>Bioactivity: CRA-026440 is a potent, broad-spectrum HDAC inhibitor. The K_i values against recombinant HDAC isoenzymes HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10 are 4, 14, 11, 15, 7, and 20 nM respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg, 20 mg</p> 
<p>CUDC-101</p> <p style="text-align: right;">Cat. No.: HY-10223</p> <p>Bioactivity: CUDC-101 is a potent inhibitor of HDAC, EGFR, and HER2 with IC₅₀s of 4.4, 2.4, and 15.7 nM, respectively.</p> <p>Purity: 99.59%</p> <p>Clinical Data: Phase 1</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>CUDC-907 (fimepinostat)</p> <p style="text-align: right;">Cat. No.: HY-13522</p> <p>Bioactivity: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC₅₀ of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10, respectively.</p> <p>Purity: 99.95%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg</p> 


<p>Dacinostat (NVP-LAQ824; LAQ824) Cat. No.: HY-13606</p> <p>Bioactivity: Dacinostat is a potent HDAC inhibitor, with an IC₅₀ of 32 nM; Dacinostat also inhibits HDAC1 with an IC₅₀ of 9 nM, and used in cancer research.</p> <p>Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 	<p>Droxinostat (NS 41080) Cat. No.: HY-13267</p> <p>Bioactivity: Droxinostat(NS41080) is a selective inhibitor of HDAC3, HDAC6, and HDAC8 with IC₅₀ of 16.9, 2.47 and 1.46 μM, respectively; > 8-fold selective against HDAC3 and no inhibition to HDAC1, 2, 4, 5, 7, 9, and 10. IC₅₀ Value: 16.9 μM(HDAC3); 2.47 μM(HDAC6); 1.46 μM(HDAC8) Target: HDAC3/6/8 in vitro...</p> <p>Purity: 98.86% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>EDO-S101 (Tinostamustine) Cat. No.: HY-101780</p> <p>Bioactivity: EDO-S101 is a pan HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3 with IC₅₀ values of 9, 9 and 25 nM, respectively.</p> <p>Purity: 98.09% Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>Entinostat (MS-275; SNDX-275) Cat. No.: HY-12163</p> <p>Bioactivity: Entinostat is an oral and selective class I HDAC inhibitor, with IC₅₀s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively.</p> <p>Purity: 99.65% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg</p> 
<p>Givinostat (Gavinostat; ITF-2357) Cat. No.: HY-14842</p> <p>Bioactivity: Givinostat is a HDAC inhibitor with an IC₅₀ of 198 and 157 nM for HDAC1 and HDAC3, respectively.</p> <p>Purity: >98% Clinical Data: Phase 3 Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Givinostat hydrochloride (Gavinostat hydrochloride; ITF-2357 hydrochloride) Cat. No.: HY-14842A</p> <p>Bioactivity: Givinostat hydrochloride is a HDAC inhibitor with an IC₅₀ of 198 and 157 nM for HDAC1 and HDAC3, respectively.</p> <p>Purity: >98% Clinical Data: Phase 3 Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Givinostat hydrochloride monohydrate (Gavinostat hydrochloride monohydrate; ...) Cat. No.: HY-14842B</p> <p>Bioactivity: Givinostat hydrochloride monohydrate is a HDAC inhibitor with an IC₅₀ of 198 and 157 nM for HDAC1 and HDAC3, respectively.</p> <p>Purity: 98.0% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>HDAC-IN-3 Cat. No.: HY-19772</p> <p>Bioactivity: HDAC-IN-3 is a histone deacetylase (HDAC) inhibitor, extracted from patent WO/2008040934 A1.</p> <p>Purity: 99.52% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>HDAC-IN-4 (CXD101) Cat. No.: HY-100748</p> <p>Bioactivity: HDAC-IN-4 is a histone deacetylase (HDAC) inhibitor, extracted from patent WO/2007045844 A1 20070426.</p> <p>Purity: 98.14% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>HDAC-IN-5 Cat. No.: HY-18362</p> <p>Bioactivity: HDAC-IN-5 is a histone deacetylase (HDAC) inhibitor.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p> 


<p>HDAC6-IN-1</p> <p style="text-align: right;">Cat. No.: HY-18947</p> <p>Bioactivity: HDAC6-IN-1 is a potent and selective inhibitor for HDAC6 with an IC₅₀ of 17 nM and shows 25-fold and 200-fold selectivity relative to HDAC1 (IC₅₀=422 nM) and HDAC8 (IC₅₀=3398 nM), respectively.</p> <p>Purity: 98.49%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>HDAC8-IN-1</p> <p style="text-align: right;">Cat. No.: HY-111342</p> <p>Bioactivity: HDAC8-IN-1 is a HDAC8 inhibitor with an IC₅₀ of 27.2 nM.</p> <p>Purity: 99.59%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>HPOB</p> <p style="text-align: right;">Cat. No.: HY-19747</p> <p>Bioactivity: HPOB is a highly potent and selective inhibitor of histone deacetylase 6 (HDAC6) with IC₅₀ of 56 nM, >30 fold less potent against other HDACs.</p> <p>Purity: 95.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>ITSA-1</p> <p style="text-align: right;">Cat. No.: HY-100508</p> <p>Bioactivity: ITSA-1 is membrane permeable and specifically suppresses TSA inhibition of HDAC (histone deacetylase), but not other HDAC inhibitors.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>LMK-235</p> <p style="text-align: right;">Cat. No.: HY-18998</p> <p>Bioactivity: LMK-235 is a potent and selective HDAC4/5 inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11 and HDAC8, with IC₅₀s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.</p> <p>Purity: 99.46%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>M344</p> <p style="text-align: right;">Cat. No.: HY-13506</p> <p>(D 237; MS 344)</p> <p>Bioactivity: M344 is an inhibitor of histone deacetylase (IC₅₀=100 nM) and an inducer of terminal cell differentiation.</p> <p>Purity: 99.36%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p>MC1568</p> <p style="text-align: right;">Cat. No.: HY-16914</p> <p>Bioactivity: MC1568 is a selective class II (IIa) histone deacetylase (HDAC II) inhibitor, used for cancer research.</p> <p>Purity: 98.02%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 	<p>Mocetinostat</p> <p style="text-align: right;">Cat. No.: HY-12164</p> <p>Bioactivity: Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC₅₀s of 0.15, 0.29, 1.66 and 0.59 μM for HDAC1, HDAC2, HDAC3 and HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.</p> <p>Purity: 99.49%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 
<p>Nexturastat A</p> <p style="text-align: right;">Cat. No.: HY-16699</p> <p>Bioactivity: Nexturastat A is a potent and selective HDAC6 inhibitor with IC₅₀ of 5 nM; no inhibition on other HDAC forms.</p> <p>Purity: 97.92%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>NKL 22</p> <p style="text-align: right;">Cat. No.: HY-100384</p> <p>Bioactivity: NKL 22 is a HDAC inhibitor. The value of IC₅₀ is 78 μM. NKL 22 increase frataxin protein concentrations. NKL 22 inhibitors increase FXN mRNA in FRDA lymphocytes. HDAC inhibitors act directly on FXN. [1]</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 


<p>Oxamflatin (Metacept-3) Cat. No.: HY-102033</p> <p>Bioactivity: Oxamflatin (Metacept-3) is a potent HDAC inhibitor with an IC₅₀ of 15.7 nM.</p> <p>Purity: 98.67% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg</p> 	<p>Panobinostat (LBH589; NVP-LBH589) Cat. No.: HY-10224</p> <p>Bioactivity: Panobinostat is a non-selective histone deacetylase (HDAC) inhibitor.</p> <p>Purity: 98.42% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</p> 
<p>PCI-24781 (CRA 024781; CRA 24781; Abexinostat) Cat. No.: HY-10990</p> <p>Bioactivity: PCI-24781 (Abexinostat; CRA 24781) is a novel pan- HDAC inhibitor mostly targeting HDAC1 with K_i of 7 nM.</p> <p>Purity: 97.94% Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>PCI-34051 Cat. No.: HY-15224</p> <p>Bioactivity: PCI-34051 is a potent and selective HDAC8 inhibitor with IC₅₀ of 10 nM, with >200-fold selectivity over the other HDAC isoforms.</p> <p>Purity: 99.46% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Pimelic Diphenylamide 106 (RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII) Cat. No.: HY-19348</p> <p>Bioactivity: Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I HDAC (HDAC 1, 2, and 3, with IC50 values of 150 nM, 760nM, and 370 nM, respectively), demonstrating no activity against class II HDACs.</p> <p>Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Pomiferin (NSC 5113; Pomiferin (flavonoid)) Cat. No.: HY-N4315</p> <p>Bioactivity: Pomiferin, a flavonoid from the fruits of <i>Maclura pomifera</i>, acts as a potential inhibitor of HDAC, with an IC₅₀ of 1.05 μM, and also potently inhibits mTOR (IC₅₀ 6.2 μM).</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg</p> 
<p>Pracinostat (SB939) Cat. No.: HY-13322</p> <p>Bioactivity: Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC₅₀s of 40-140 nM, used for cancer research.</p> <p>Purity: 98.40% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>PTACH (NCH-51) Cat. No.: HY-12954</p> <p>Bioactivity: PTACH (NCH-51) is a SAHA-based novel inhibitor of human HDAC. PTACH exerts potent growth inhibition against various human cancer cells, with EC50 values ranging from 1 to 10 μM.</p> <p>Purity: 99.36% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Quisinostat (JNJ-26481585) Cat. No.: HY-15433</p> <p>Bioactivity: Quisinostat (JNJ-26481585) is an orally available, potent HDAC inhibitor with an IC₅₀ of 0.11 nM for HDAC1.</p> <p>Purity: 98.0% Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Resminostat (RAS2410; 4SC-201) Cat. No.: HY-14718</p> <p>Bioactivity: Resminostat is a potent inhibitor of HDAC1, HDAC3 and HDAC6, with mean IC₅₀ values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC₅₀ of 877 nM.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 10 mg, 50 mg, 100 mg</p> 


<p>Resminostat hydrochloride (RAS2410 hydrochloride; 45C-201 hydrochloride) Cat. No.: HY-14718A</p> <p>Bioactivity: Resminostat hydrochloride is a potent inhibitor of HDAC1, HDAC3 and HDAC6, with mean IC₅₀ values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC₅₀ of 877 nM.</p> <p>Purity: 98.02% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 	<p>RG2833 (RGFP109) Cat. No.: HY-16425</p> <p>Bioactivity: RG2833 is a brain-penetrant HDAC inhibitor with IC₅₀ of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.</p> <p>Purity: 99.14% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>RGFP966 Cat. No.: HY-13909</p> <p>Bioactivity: RGFP966 is a selective HDAC3 inhibitor with an IC₅₀ of 80 nM and no effective inhibition of any other HDAC at concentrations up to 15 μM.</p> <p>Purity: 98.99% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Romidepsin (FK 228; FR 901228; NSC 630176) Cat. No.: HY-15149</p> <p>Bioactivity: Romidepsin is a potent HDAC1 and HDAC2 inhibitor with IC₅₀s of 36 and 47 nM, respectively.</p> <p>Purity: 99.52% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg</p> 
<p>Santacruzamate A (CAY-10683) Cat. No.: HY-N0931</p> <p>Bioactivity: Santacruzamate A is a potent and selective histone deacetylase inhibitor.</p> <p>Purity: 99.72% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg</p> 	<p>Scriptaid (Scriptide; GCK1026) Cat. No.: HY-15489</p> <p>Bioactivity: Scriptaid is a potent histone deacetylase (HDAC) inhibitor, used in cancer research.</p> <p>Purity: 99.12% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 
<p>Sodium Butyrate (Butanoic acid sodium salt) Cat. No.: HY-B0350A</p> <p>Bioactivity: Sodium Butyrate is a histone deacetylase (HDAC) inhibitor, has anti-tumor effects in several cancers.</p> <p>Purity: 98.00% Clinical Data: Phase 3 Size: 10mM x 1mL in Water, 1 g, 5 g</p> 	<p>Sodium phenylbutyrate (Sodium 4-phenylbutyrate; TriButyrate) Cat. No.: HY-15654</p> <p>Bioactivity: Sodium phenylbutyrate is a histone deacetylase (HDAC) inhibitor, used in cancer and infection research.</p> <p>Purity: 99.75% Clinical Data: Launched Size: 10mM x 1mL in Water, 100 mg, 200 mg</p> 
<p>SR-4370 Cat. No.: HY-111400</p> <p>Bioactivity: SR-4370 is an inhibitor of HDAC, with IC₅₀s of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC6, respectively.</p> <p>Purity: 98.33% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Sulforaphane Cat. No.: HY-13755</p> <p>Bioactivity: Sulforaphane is an isothiocyanate present naturally in widely consumed vegetables; has shown anticancer and cardioprotective activities.</p> <p>Purity: 98.90% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg, 100 mg</p> 


<p>Tasquinimod (ABR-215050) Cat. No.: HY-10528</p> <p>Bioactivity: Tasquinimod is an oral allosteric modulator of HDAC4 with a K_d of 10–30 nM for the regulatory Zn²⁺ binding domain of HDAC4.</p> <p>Purity: 99.85% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Tenovin 6 Hydrochloride (Tenovin 2) Cat. No.: HY-15510B</p> <p>Bioactivity: Tenovin-6 Hydrochloride is a water soluble inhibitor of SIRT1 and SIRT2, slightly inhibits HDAC8, and is also a potent activator of p53, with IC_{50}s of 21 μM, 10 μM, 67 μM for SirT1, SirT2, and SirT3, respectively.</p> <p>Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Tenovin-6 Cat. No.: HY-15510</p> <p>Bioactivity: Tenovin-6 is a water soluble inhibitor of SIRT1 and SIRT2, slightly inhibits HDAC8, and is also a potent activator of p53, with IC_{50}s of 21 μM, 10 μM, and 67 μM for SirT1, SirT2, and SirT3, respectively.</p> <p>Purity: 98.24% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>TMP195 Cat. No.: HY-18361</p> <p>Bioactivity: TMP195 is a selective class IIa histone deacetylase (HDAC) inhibitor with an IC_{50} of 300 nM.</p> <p>Purity: 99.42% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>TMP269 Cat. No.: HY-18360</p> <p>Bioactivity: TMP269 is a novel and selective class IIa histone deacetylase (HDAC) inhibitor with IC_{50}s of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.</p> <p>Purity: 98.42% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg</p> 	<p>Trichostatin A (TSA) Cat. No.: HY-15144</p> <p>Bioactivity: Trichostatin A is a potent and specific inhibitor of HDAC class I/II, with an IC_{50} value of 1.8 nM for HDAC.</p> <p>Purity: 99.53% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg</p> 
<p>Tubacin Cat. No.: HY-13428</p> <p>Bioactivity: Tubacin is a potent and selective inhibitor of HDAC6, with an IC_{50} value of 4 nM and approximately 350-fold selectivity over HDAC1.</p> <p>Purity: 98.87% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg</p> 	<p>Tubastatin A Hydrochloride (Tubastatin A HCl; TSA HCl) Cat. No.: HY-13271</p> <p>Bioactivity: Tubastatin A (Hydrochloride) is a potent and selective HDAC6 inhibitor with IC_{50} of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more).</p> <p>Purity: 98.11% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 
<p>Tubastatin-A Cat. No.: HY-13271A</p> <p>Bioactivity: Tubastatin A is a potent and selective HDAC6 inhibitor with IC_{50} of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more).</p> <p>Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>Tucidinostat (Chidamide; HBI-8000; CS 055) Cat. No.: HY-109015</p> <p>Bioactivity: Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC_{50}s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC_{50}s, 733 nM, 432 nM, respectively), and shows...</p> <p>Purity: 98.01% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 

UF010	Cat. No.: HY-18976
Bioactivity:	UF010 is a potent and selective HDAC inhibitor with IC ₅₀ ~0.06 μM, 0.1 μM, 0.5 μM and 1.5 μM for HDACs 3, 2, 1 and 8, respectively. It has > 6-fold selectivity over other HDACs. IC ₅₀ value: 0.06 μM (HDAC3), 0.1 μM (HDAC2), 0.5 μM (HDAC1), 1.5 μM (HDAC 8) Target: HDAC in vitro: UF010 is a competitive...
Purity:	99.36%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg
	

Valproic acid (VPA; 2-Propylpentanoic Acid)	Cat. No.: HY-10585
Bioactivity:	Valproic acid is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀ : 400 μM), and induces proteasomal degradation of HDAC2 ; Valproic acid sodium salt is used in the treatment of epilepsy, bipo...
Purity:	98.67%
Clinical Data:	Launched
Size:	10mM x 1mL in DMSO, 1 g, 5 g
	

Valproic acid sodium salt (Sodium Valproate)	Cat. No.: HY-10585A
Bioactivity:	Valproic acid sodium salt is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀ : 400 μM), and induces proteasomal degradation of HDAC2 ; Valproic acid sodium salt is used in the treatment of epilepsy, bipo...
Purity:	98.0%
Clinical Data:	Launched
Size:	10mM x 1mL in Water, 1 g, 5 g
	


Vorinostat (SAHA)	Cat. No.: HY-10221
Bioactivity:	Vorinostat is a potent and orally available inhibitor of HDAC1 , HDAC2 and HDAC3 (Class I) , HDAC7 (Class II) and HDAC11 (Class IV) , with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively.
Purity:	99.90%
Clinical Data:	Launched
Size:	10mM x 1mL in DMSO, 250 mg, 500 mg, 1 g, 5 g
	

WT-161	Cat. No.: HY-100871
Bioactivity:	WT-161 is a potent and selective HDAC6 inhibitor with an IC₅₀ of 0.40 nM.
Purity:	98.0%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
	

Histone Acetyltransferase

HATs;HAT

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)

The histone acetyltransferase (HAT) enzymes p300 and CBP are closely related paralogs that serve as transcriptional coactivators. The p300 and CBP catalyze the acetylation of Lys residues in histones and other proteins. Serving as transcriptional coactivators, p300 and CBP participate in numerous ways to regulate cell growth, differentiation, and gene expression across many organ systems and physiologic pathways. Dysregulation of p300/CBP by mutation, altered expression, or other mechanisms has been linked to disease states, including various malignancies such as acute leukemias and prostate cancer. Furthermore, p300/CBP is critical in development as evidenced by the genetic disorder Rubinstein-Taybi syndrome, which

occurs with loss of function mutations in single alleles of either p300 or CBP.

Inhibitors of p300/CBP HAT activity have been developed and are under investigation as therapeutics for a number of diseases.

Histone Acetyltransferase Inhibitors & Modulators

<p>A-485</p> <p style="text-align: right;">Cat. No.: HY-107455</p> <p>Bioactivity: A-485 is a potent and selective catalytic inhibitor of p300/CBP with IC₅₀s of 9.8nM and 2.6nM for p300 and CBP, respectively.</p> <p>Purity: 99.08%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Anacardic Acid (Hydroginkgolic acid)</p> <p style="text-align: right;">Cat. No.: HY-N2020</p> <p>Bioactivity: Anacardic Acid, extracted from cashew nut shell liquid, is a histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC₅₀s of 8.5 μM and 5 μM, respectively.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg</p> 
<p>C646</p> <p style="text-align: right;">Cat. No.: HY-13823</p> <p>Bioactivity: C646 is a selective and competitive histone acetyltransferase p300 inhibitor with K_i of 400 nM, and is less potent for other acetyltransferases.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 	<p>CPI-637</p> <p style="text-align: right;">Cat. No.: HY-100482</p> <p>Bioactivity: CPI-637 is a potent and selective CBP/EP300 bromodomains inhibitor with IC₅₀ of 0.03±0.01μM and 11.0±0.6 μM for CBP/EP300 and BRD4, respectively. IC₅₀:0.03±0.01μM (CBP/EP300)[1] IC₅₀:11.0±0.6 μM(BRD4)[1] CPI-637, which demonstrated substantial biochemical potency that was...</p> <p>Purity: 99.94%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Curcumin (Indian Saffron; Turmeric yellow; Natural Yellow 3; Diferuloylmethane)</p> <p style="text-align: right;">Cat. No.: HY-N0005</p> <p>Bioactivity: Curcumin is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetyltransferase (HATs) and also shows inhibitory effects on NF-κB and...</p> <p>Purity: 99.66%</p> <p>Clinical Data: Phase 4</p> <p>Size: 10mM x 1mL in DMSO, 100 mg, 500 mg</p> 	<p>EML 425</p> <p style="text-align: right;">Cat. No.: HY-110263</p> <p>Bioactivity: EML425 is a potent and selective CREB binding protein (CBP)/p300 inhibitor with IC₅₀s of 2.9 and 1.1 μM, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg</p> 
<p>GNE-049</p> <p style="text-align: right;">Cat. No.: HY-108435</p> <p>Bioactivity: GNE-049 is a highly potent and selective CBP inhibitor with an IC₅₀ of 1.1 nM in TR-FRET assay. GNE-049 also inhibits BRET and BRD4(1) with IC₅₀s of 12 nM and 4200 nM, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 mg, 250 mg</p> 	<p>GNE-272</p> <p style="text-align: right;">Cat. No.: HY-100726</p> <p>Bioactivity: GNE-272 is a potent and selective in vivo probe for the bromodomains of CBP/EP300 with IC₅₀ values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>GNE-781</p> <p style="text-align: right;">Cat. No.: HY-108696</p> <p>Bioactivity: GNE-781 is a highly potent and selective CBP inhibitor with an IC₅₀ of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC₅₀s of 6.2 nM and 5100 nM, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 mg, 250 mg</p> 	<p>GSK 4027</p> <p style="text-align: right;">Cat. No.: HY-101027</p> <p>Bioactivity: GSK 4027 is a chemical probe for the PCAF/ GCNS bromodomain with an pIC₅₀ of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.</p> <p>Purity: 98.01%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 

<p>GSK4028</p> <p style="text-align: right;">Cat. No.: HY-101027A</p> <p>Bioactivity: GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC₅₀ of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>HAT-IN-1</p> <p style="text-align: right;">Cat. No.: HY-103669</p> <p>Bioactivity: HAT-IN-1 is an inhibitor of HAT, used in the research of cancer.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p> 
<p>Histone Acetyltransferase Inhibitor II</p> <p style="text-align: right;">Cat. No.: HY-100734</p> <p>Bioactivity: Histone Acetyltransferase Inhibitor II is a potent and cell permeable p300 inhibitor, with an IC₅₀ of 5 μM; Histone Acetyltransferase Inhibitor II can be used in cancer research.</p> <p>Purity: 99.05%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>I-CBP112</p> <p style="text-align: right;">Cat. No.: HY-19541</p> <p>Bioactivity: I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that targets the CBP/p300 bromodomains.</p> <p>Purity: 98.57%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>MG 149</p> <p style="text-align: right;">Cat. No.: HY-15887</p> <p>Bioactivity: MG149 is a selective and potent Tip60 inhibitor with IC50 of 74 uM, similar potency for MOF(IC50= 47 uM); little potent for PCAF and p300(IC50 >200 uM). IC50 value: 74/47 uM (Tip60/MOF) [1] Target: Tip60/MOF MG 149, at 200 μM, inhibited about 90% of Tip60 activity but had no inhibitory impact on...</p> <p>Purity: 99.48%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>MOZ-IN-2</p> <p style="text-align: right;">Cat. No.: HY-102059</p> <p>Bioactivity: MOZ-IN-2 is an inhibitor of protein MOZ, a member of histone acetyltransferases, with an IC₅₀ of 125 μM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p> 
<p>MOZ-IN-3</p> <p style="text-align: right;">Cat. No.: HY-102060</p> <p>Bioactivity: MOZ-IN-3 is an inhibitor of MOZ, a member of histone acetyltransferases, with an IC₅₀ of 55 nM.</p> <p>Purity: 99.70%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>PF-CBP1 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-19999A</p> <p>Bioactivity: PF-CBP1 hydrochloride is a highly selective inhibitor of the CREB binding protein bromodomain. Target: CREB in vitro: PF-CBP1 modulates key inflammatory genes in primary macrophages. PF-CBP1 downregulates RGS4 in neurons, a target linked to Parkinson's disease. PF-CBP1 is 139-fold selective...</p> <p>Purity: 99.77%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>Remodelin</p> <p style="text-align: right;">Cat. No.: HY-16706</p> <p>Bioactivity: Remodelin is a novel potent and selective inhibitor of the acetyl-transferase protein NAT10. IC50 value: Target: NAT10 inhibitor Remodelin can improve nuclear architecture, chromatin organization, and fitness of both human lamin A/C-depleted cells and HGPS-derived patient cells, and...</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>Remodelin hydrobromide</p> <p style="text-align: right;">Cat. No.: HY-16706A</p> <p>Bioactivity: Remodelin HBr salt is a novel potent and selective inhibitor of the acetyl-transferase protein NAT10. IC50 value: Target: NAT10 inhibitor Remodelin can improve nuclear architecture, chromatin organization, and fitness of both human lamin A/C-depleted cells and HGPS-derived patient cells, and...</p> <p>Purity: 99.16%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 

SGC-CBP30


Cat. No.: HY-15826

Bioactivity: SGC-CBP30 is a potent CREBBP/EP300 bromodomain inhibitor with IC₅₀ of 21-69 and 38 nM for CREBBP and EP300 bromodomains, respectively. IC₅₀ Value: 21-69 nM(for CREBBP); 38 nM(for EP300) Target: Others in vivo: SGC-CBP30 is a highly potent and selective p300/CBP bromodomain inhibitor (IC₅₀...

Purity: 99.19%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



TPOP146


Cat. No.: HY-100697

Bioactivity: TPOP146 is a selective **CBP/P300** benzoxazepine bromodomain inhibitor with **K_d** values of 134 nM and 5.02 μM for CBP and BRD4.

Purity: 99.66%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



WM-1119


Cat. No.: HY-102058

Bioactivity: WM-1119 is a highly potent, selective KAT6A/B inhibitor, with an IC₅₀ of 0.25 μM for KAT6A, a K_D of 2 nM for KAT6A, a K_D of 2.2 μM for KAT5, and a K_D of 0.5 μM for KAT7.

Purity: 98.0%


Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Histone Demethylase

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)

There are two classes of enzymes involved in histone methylation: methyltransferases and demethylases. While methyltransferases are responsible for establishing methylation patterns, demethylases are capable of removing methyl groups not only from histones but other proteins as well. Histone demethylases not only target methylated sites on histone tails but also interact with methylated sites on non-histone proteins, such as p53.

Histone lysine demethylases (KDMs) are of interest as drug targets due to their regulatory roles in chromatin organization and their tight associations with diseases including cancer and mental disorders.

JMJD1A (also named KDM3A) is a demethylase that removes methyl from histone lysine H3K9. It plays important roles in various cellular processes, including spermatogenesis, energy metabolism, regulation of stem cell and gender display.

Jumonji domain-containing 3 (Jmjd3) has been identified as a histone demethylase, which specifically catalyzes the removal of methylation from H3K27me3.

Histone Demethylase Inhibitors & Modulators


<p>AS8351 (NSC51355) Cat. No.: HY-100744</p> <p>Bioactivity: AS8351 is a KDMSB inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells.</p> <p>Purity: 99.70% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>CBB1003 Cat. No.: HY-15774</p> <p>Bioactivity: CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg</p> 
<p>CBB1003 hydrochloride Cat. No.: HY-15774A</p> <p>Bioactivity: CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg</p> 	<p>CBB1007 Cat. No.: HY-15313</p> <p>Bioactivity: CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 uM for hLSD1).</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>CBB1007 hydrochloride Cat. No.: HY-15313B</p> <p>Bioactivity: CBB1007 Hcl is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 uM for hLSD1).</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>CBB1007 trihydrochloride Cat. No.: HY-15313C</p> <p>Bioactivity: CBB1007 trihydrochloride is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 uM for hLSD1).</p> <p>Purity: 96.58% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Corin Cat. No.: HY-111048</p> <p>Bioactivity: Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC), with a K_i(inact) of 110 nM for LSD1 and an IC₅₀ of 147 nM for HDAC1.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 500 mg, 250 mg</p> 	<p>CPI-455 Cat. No.: HY-100421</p> <p>Bioactivity: CPI-455 is a specific KDMS inhibitor.</p> <p>Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>Daminozide Cat. No.: HY-13643</p> <p>Bioactivity: Daminozide(DMASA; DIMG; B 995), a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily. IC50 Value: Target: KDM2/7 JmjC Inhibition of shoot elongation in dwarf and tall peas by the 1,1-dimethylhydrazide of succinic acid (B-995) was correlated with the inhibition of the oxidation of...</p> <p>Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 g, 5 g</p> 	<p>DDP-38003 dihydrochloride Cat. No.: HY-19612A</p> <p>Bioactivity: DDP-38003 dihydrochloride is a novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC₅₀ of 84 nM.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 

<p>DDP-38003 trihydrochloride</p> <p style="text-align: right;">Cat. No.: HY-19612B</p> <p>Bioactivity: DDP-38003 trihydrochloride is a novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC₅₀ of 84 nM.</p> <p>Purity: 98.74%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>GSK 690 Hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-117226A</p> <p>Bioactivity: GSK 690 (Hydrochloride) is a reversible inhibitor of lysine specific demethylase 1 (LSD1), with a K_d value of 9 nM and a biochemical IC₅₀ of 37 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p> 
<p>GSK-J1</p> <p style="text-align: right;">Cat. No.: HY-15648</p> <p>Bioactivity: GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC₅₀ of 60 nM towards KDM6B.</p> <p>Purity: 99.92%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 	<p>GSK-J1 lithium salt</p> <p style="text-align: right;">Cat. No.: HY-15648D</p> <p>Bioactivity: GSK-J1 lithium salt is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC₅₀ of 60 nM towards KDM6B.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mg, 50 mg</p> 
<p>GSK-J2</p> <p style="text-align: right;">Cat. No.: HY-15648A</p> <p>Bioactivity: GSK-J2 is an isomer of GSK-J1 that does not have any specific activity. GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A.</p> <p>Purity: 98.82%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 	<p>GSK-J4</p> <p style="text-align: right;">Cat. No.: HY-15648B</p> <p>Bioactivity: GSK-J4 is a potent H3K27me3 histone lysine demethylase (KDM) inhibitor, with IC₅₀s of 8.6 μM and 6.6 μM against KDM6B and KDM6A, respectively.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 
<p>GSK-LSD1 Dihydrochloride</p> <p style="text-align: right;">Cat. No.: HY-100546A</p> <p>Bioactivity: GSK-LSD1 Dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 16 nM.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>GSK2879552</p> <p style="text-align: right;">Cat. No.: HY-18632</p> <p>Bioactivity: GSK2879552 is an orally available, irreversible inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.</p> <p>Purity: 99.94%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>IOX1</p> <p style="text-align: right;">Cat. No.: HY-12304</p> <p>Bioactivity: IOX1 is the most potent broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases; IC50 for KDM4A/KDM3A is 0.6/0.1 uM. IC50 value: 0.6/0.1 uM(KDM4A/KDM3A) [1] Target: JmjC KDMs inhibitor IOX1 is the most potent representative panel of 2OG oxygenases, including.</p> <p>Purity: 97.41%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>JIB-04</p> <p style="text-align: right;">Cat. No.: HY-13953</p> <p>Bioactivity: JIB-04 is a pan-selective Jumonji histone demethylase inhibitor with IC₅₀s of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.</p> <p>Purity: 97.95%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 


<p>KDM4D-IN-1</p> <p style="text-align: right;">Cat. No.: HY-101928</p> <p>Bioactivity: KDM4D-IN-1 is a new histone lysine demethylase 4D (KDM4D) inhibitor with an IC₅₀ value of 0.41±0.03 μM.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>KDM5-IN-1</p> <p style="text-align: right;">Cat. No.: HY-100422</p> <p>Bioactivity: KDM5-IN-1 is a potent, selective and orally bioavailable KDM5 inhibitor with an IC₅₀ of 15.1 nM.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>KDM5A-IN-1</p> <p style="text-align: right;">Cat. No.: HY-100014</p> <p>Bioactivity: KDM5A-IN-1 is an inhibitor histone demethylases. Target: Histone Demethylase</p> <p>Purity: 99.76%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>ML324</p> <p style="text-align: right;">Cat. No.: HY-12725</p> <p>Bioactivity: ML324 is a potent JMJD2 demethylase inhibitor with demonstrated antiviral activity.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 
<p>NCGC00244536 (KDM4B Inhibitor B3)</p> <p style="text-align: right;">Cat. No.: HY-101799</p> <p>Bioactivity: NCGC00244536 is a potent KDM4B inhibitor with an IC₅₀ of 10 nM.</p> <p>Purity: 98.57%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>NCGC00247743</p> <p style="text-align: right;">Cat. No.: HY-112308</p> <p>Bioactivity: NCGC00247743 is a histone lysine demethylase KDM4 inhibitor.</p> <p>Purity: 99.35%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg</p> 
<p>ORY-1001(trans)</p> <p style="text-align: right;">Cat. No.: HY-12782T</p> <p>Bioactivity: ORY-1001 trans is a selective irreversible lysine (K)-specific demethylase 1A (KDM1A/ LSD1) inhibitor.</p> <p>Purity: 99.14%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>QC6352</p> <p style="text-align: right;">Cat. No.: HY-104048</p> <p>Bioactivity: QC6352 is a potent KDM4C inhibitor with an IC₅₀ of 35 nM.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>S 2101</p> <p style="text-align: right;">Cat. No.: HY-110277</p> <p>Bioactivity: S 2101 is a lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 0.99 μM, K_i of 0.61 μM and K_{inact}/K_i of 4560 M/s.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg</p> 	<p>Seclidemstat (SP-2577)</p> <p style="text-align: right;">Cat. No.: HY-103713</p> <p>Bioactivity: Seclidemstat is a potent LSD1 inhibitor, with a mean IC₅₀ of 127 nM.</p> <p>Purity: 98.78%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 

SP2509

Cat. No.: HY-12635

Bioactivity: SP2509 is a potent and selective antagonist of **lysine specific demethylase 1 (LSD1)** with IC_{50} of 13 nM.**Purity:** 98.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg**T-3775440 hydrochloride**

Cat. No.: HY-103085


Bioactivity: T-3775440 (hydrochloride) is an irreversible **LSD1 inhibitor** with an IC_{50} value of 2.1 nM.**Purity:** >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg**Tranlycypromine hemisulfate** (dl-Tranlycypromine hemisulfate;
trans-2-Phenylcyclopropylamine hemisulfate salt) Cat. No.: HY-B1496**Bioactivity:** Tranlycypromine hemisulfate is an irreversible, nonselective **MAO** inhibitor used in the treatment of depression.**Purity:** 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water,
100 mg**Vafidemstat**

Cat. No.: HY-112623

Bioactivity: Vafidemstat is a dual lysine-specific histone demethylase (**LSD1**)/ **MAO-B** inhibitor.**Purity:** >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Histone Methyltransferase

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)






Histone modifications play critical roles in regulating both global and stage-specific gene expression. Methylation on histones H3K4, H3K36 and H3K79 is generally associated with gene activation, whereas methylation on histones H3K9 and H3K27 is generally associated with gene repression. Histone lysine methylation is dynamically regulated by site-specific methyltransferases and demethylases. EZH2 (the catalytic subunit of PRC2) is responsible for the methylation of H3K27 in cells.

DOT1L is a histone H3 lysine 79 methyltransferase whose inhibition increases the yield of induced pluripotent stem cells (iPSCs). EPZ-5676 is a potent and selective DOT1L inhibitor.

Crucial to PRC2 activity, the histone methyltransferase enhancer of zeste homolog 2 (EZH2) tri-methylates lysine 27 of histone 3 (H3K27me₃), leading to chromatin condensation and transcriptional repression.




Histone Methyltransferase Inhibitors & Modulators


<p>3-Deazaneplanocin A hydrochloride (DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride) Cat. No.: HY-12186</p> <p>Bioactivity: 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor.</p> <p>Purity: 99.76% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 25 mg</p> 	<p>A-366 Cat. No.: HY-12583</p> <p>Bioactivity: A-366 is a potent histone methyltransferase G9a inhibitor with an IC₅₀ of 3.3 nM.</p> <p>Purity: 98.47% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p>A-893 Cat. No.: HY-19563</p> <p>Bioactivity: A-893 is a cell-active inhibitor of Methyltransferase SMYD2, with an IC₅₀ of 2.8 nM.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p> 	<p>AMI-1 Cat. No.: HY-18962</p> <p>Bioactivity: AMI-1 is a potent, cell-permeable compound which inhibits protein arginine N-methyltransferases (PRMTs), including human PRMT1 (IC₅₀ = 8.8μM) and yeast-Hmt1p (IC₅₀ = 3.0μM), by blocking peptide-substrate binding.</p> <p>Purity: 99.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg</p> 
<p>Amodiaquin dihydrochloride dihydrate (Amodiaquin dihydrochloride dihydrate) Cat. No.: HY-B1322</p> <p>Bioactivity: Amodiaquine dihydrochloride dihydrate is a histamine N-methyltransferase inhibitor, used as an antimalarial and anti-inflammatory agent. Target: histamine N-methyltransferase Amodiaquine has been shown to be more effective than chloroquine in treating chloroquine-resistant Plasmodium...</p> <p>Purity: 99.98% Clinical Data: Launched Size: 10mM x 1mL in Water, 100 mg</p> 	<p>AZ505 Cat. No.: HY-15226</p> <p>Bioactivity: AZ505 is a potent and selective SMYD2 inhibitor with IC₅₀ of 0.12 μM.</p> <p>Purity: 99.99% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>AZ505 ditrifluoroacetate Cat. No.: HY-15226A</p> <p>Bioactivity: AZ505 ditrifluoroacetate is a potent and selective SMYD2 inhibitor with IC₅₀ of 0.12 μM.</p> <p>Purity: 99.99% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>BAY-598 Cat. No.: HY-19546</p> <p>Bioactivity: BAY-598 is selective small molecule inhibitor of SMYD2.</p> <p>Purity: 99.30% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>BCI-121 Cat. No.: HY-21972</p> <p>Bioactivity: BCI-121 is a SMYD3 inhibitor that impairs the proliferation of cancer cell.</p> <p>Purity: 97.74% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>BIX-01294 Cat. No.: HY-10587</p> <p>Bioactivity: BIX-01294 is an inhibitor of G9a Histone Methyltransferase with IC₅₀ of 1.9 μM.</p> <p>Purity: 98.61% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 


<p>BIX-01338 hydrate (BIX01338 hydrate; BIX 01338 hydrate) Cat. No.: HY-12991A</p> <p>Bioactivity: BIX-01338 hydrate is a histone lysine methyltransferase inhibitor.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p> 	<p>BRD4770 Cat. No.: HY-16705</p> <p>Bioactivity: BRD4770 is a novel G9a(EHMT2) inhibitor with EC50 of 5 uM (trimethylated H3K9 in PANC-1 cell).</p> <p>Purity: 99.87% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 
<p>BRD9539 Cat. No.: HY-15647</p> <p>Bioactivity: BRD9539 inhibits G9a activity with an IC50 of 6.3 μM, inhibits PRC2 activity with a similar IC50.</p> <p>Purity: 99.70% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>BVT948 Cat. No.: HY-100625</p> <p>Bioactivity: BVT948 is a protein tyrosine phosphatase (PTP) inhibitor which can also inhibit several cytochrome P450 (P450) isoforms and lysine methyltransferase SETD8.</p> <p>Purity: 99.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg</p> 
<p>C-7280948 Cat. No.: HY-15890</p> <p>Bioactivity: C-7280948 is a PRMT1 inhibitor.</p> <p>Purity: 99.96% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 	<p>CARM1-IN-1 Cat. No.: HY-12759</p> <p>Bioactivity: CARM1-IN-1 is a potent and specific CARM1(Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 uM; shows very low activity against PRMT1 and SET7(IC50 > 600 uM).</p> <p>Purity: 95.09% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p>CARM1-IN-1 hydrochloride Cat. No.: HY-12759A</p> <p>Bioactivity: CARM1-IN-1 hydrochloride is a potent and specific CARM1(Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 uM; shows very low activity against PRMT1 and SET7(IC50 > 600 uM).</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>Chaetocin Cat. No.: HY-N2019</p> <p>Bioactivity: Chaetocin is a specific inhibitor of the histone methyltransferase (HMT) SU(VAR)3-9 with an IC₅₀ of 0.6 μM for SU(VAR)3-9. It also inhibits thioredoxin reductase (TrxR) with an IC₅₀ of 4 μM.</p> <p>Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg</p> 
<p>CPI-1205 Cat. No.: HY-100021</p> <p>Bioactivity: CPI-1205, a highly potent and selective EZH2 inhibitor (biochemical IC₅₀=2 nM, cellular EC₅₀=32 nM).</p> <p>Purity: 99.23% Clinical Data: Phase 1 Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>Dot1L-IN-2 Cat. No.: HY-111390</p> <p>Bioactivity: Dot1L-IN-2 is a potent, selective and orally bioavailable inhibitor of Dot1L (a histone methyltransferase), with an IC₅₀ and K_i of 0.4 nM and 0.08 nM, respectively.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p> 


<p>DZNep (3-Deazaneplanocin A; 3-Deazaneplanocin) Cat. No.: HY-10442</p> <p>Bioactivity: 3-Deazaneplanocin A is a potent histone methyltransferase EZH2 inhibitor.</p> <p>Purity: 98.12% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p> 	<p>EED226 Cat. No.: HY-101117</p> <p>Bioactivity: EED226 is a potent, selective, and orally bioavailable embryonic ectoderm development (EED) inhibitor with an IC₅₀ of 22 nM.</p> <p>Purity: 98.70% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>EI1 (Ezh2 inhibitor) Cat. No.: HY-15573</p> <p>Bioactivity: EI1 is a potent and selective EZH2 inhibitor with IC₅₀ of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.</p> <p>Purity: 99.74% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>EPZ-5676 (Pinometostat) Cat. No.: HY-15593</p> <p>Bioactivity: EPZ-5676 is a potent and selective aminonucleoside inhibitor of DOT1L histone methyltransferase with K_i of < 80 pM, demonstrating > 37,000-fold selectivity against all other PMTs tested, and inhibits H3K79 methylation in tumor.</p> <p>Purity: 99.75% Clinical Data: Phase 1 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p>EPZ-6438 (Tazemetostat; E-7438) Cat. No.: HY-13803</p> <p>Bioactivity: EPZ-6438 (Tazemetostat) is a potent, selective and orally available EZH2 inhibitor with K_i and IC₅₀ of 2.5 and 11 nM, respectively.</p> <p>Purity: 99.63% Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>EPZ004777 Cat. No.: HY-15227</p> <p>Bioactivity: EPZ004777 is a potent, selective DOT1L inhibitor with IC₅₀ of 0.4 nM.</p> <p>Purity: 99.89% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>EPZ004777 hydrochloride Cat. No.: HY-15227A</p> <p>Bioactivity: EPZ004777 hydrochloride is a potent, selective DOT1L inhibitor with IC₅₀ of 0.4 nM.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p> 	<p>EPZ005687 Cat. No.: HY-15555</p> <p>Bioactivity: EPZ005687 is a potent and selective inhibitor of EZH2 with K_i of 24 nM, and has 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.</p> <p>Purity: 98.97% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>EPZ011989 Cat. No.: HY-16986</p> <p>Bioactivity: EPZ011989 is a potent, selective orally bioavailable EZH2 inhibitor with K_i < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.</p> <p>Purity: 99.36% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>EPZ011989 trifluoroacetate (EPZ-011989 trifluoroacetate) Cat. No.: HY-16986A</p> <p>Bioactivity: EPZ011989 trifluoroacetate is a potent, selective orally bioavailable EZH2 inhibitor with K_i < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 


<p>EPZ015666</p> <p style="text-align: right;">Cat. No.: HY-12727</p> <p>Bioactivity: EPZ015666 is an orally available inhibitor of PRMT5 enzymatic activity in biochemical assays with IC₅₀ of 22 nM and broad selectivity against a panel of other histone methyltransferases.</p> <p>Purity: 98.56%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>EPZ015866</p> <p style="text-align: right;">Cat. No.: HY-100235</p> <p>Bioactivity: EPZ015866 is a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) with an IC₅₀ of 22 nM.</p> <p>Purity: 98.71%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>EPZ020411</p> <p style="text-align: right;">Cat. No.: HY-12970</p> <p>Bioactivity: EPZ020411 is a potent and selective inhibitor of PRMT6 with IC50 of 10 nM, has 10 fold selectivity for PRMT6 over PRMT1 and PRMT8.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>EPZ020411 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-12970A</p> <p>Bioactivity: EPZ020411 hydrochloride is a potent and selective inhibitor of PRMT6 with IC50 of 10 nM, has 10 fold selectivity for PRMT6 over PRMT1 and PRMT8. IC50 value: 10 nM Target: PRMT6 in vitro: EPZ020411 inhibits methylation of PRMT6 substrates in cells. EPZ020411 does-dependently inhibits H3R2 methylation in...</p> <p>Purity: 98.49%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in Water, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>EPZ031686</p> <p style="text-align: right;">Cat. No.: HY-19324</p> <p>Bioactivity: EPZ031686 is a noncompetitive inhibitor for SMYD3 and MEK2 with a Ki=1.2 and 1.1 nM respectively. In vitro: EPZ031686 have a cellular potency at a level sufficient to probe the in vitro biology of SMYD3 inhibition. The first SMYD3 inhibitor identify to show double-digit nanomolar cellular activity....</p> <p>Purity: 99.63%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>GSK126</p> <p style="text-align: right;">Cat. No.: HY-13470</p> <p>Bioactivity: GSK126 is a potent, highly selective inhibitor of EZH2 methyltransferase with an IC₅₀ of 9.9 nM.</p> <p>Purity: 99.86%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 
<p>GSK2807 Trifluoroacetate</p> <p style="text-align: right;">Cat. No.: HY-104009A</p> <p>Bioactivity: GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3, with a K_i of 14 nM.</p> <p>Purity: 95.24%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>GSK3326595</p> <p style="text-align: right;">Cat. No.: HY-101563</p> <p>Bioactivity: GSK3326595 is a potent, selective, reversible inhibitor of protein arginine methyltransferase 5 (PRMT5) with an IC₅₀ of 6.2 nM.</p> <p>Purity: 99.24%</p> <p>Clinical Data: Phase 1</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 
<p>GSK343</p> <p style="text-align: right;">Cat. No.: HY-13500</p> <p>Bioactivity: GSK343 is a highly potent and selective EZH2 inhibitor with an IC₅₀ of 4 nM.</p> <p>Purity: 98.49%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>GSK503</p> <p style="text-align: right;">Cat. No.: HY-12856</p> <p>Bioactivity: GSK503 is a potent and specific inhibitor of EZH2 methyltransferase with K_i^{APP} values of 3 to 27 nM.</p> <p>Purity: 98.99%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 


<p>HLCL-61 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-100025A</p> <p>Bioactivity: HLCL-61 hydrochloride is a first-in-class small-molecule inhibitor of PRMT5.</p> <p>Purity: 99.66%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>LLY-507</p> <p style="text-align: right;">Cat. No.: HY-19313</p> <p>Bioactivity: LLY-507 is a potent and selective inhibitor of protein-lysine methyltransferase SMYD2 with an IC₅₀ of 15 nM.</p> <p>Purity: 99.09%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg</p> 
<p>MI-2 (Menin-MLL inhibitor 2)</p> <p style="text-align: right;">Cat. No.: HY-15222</p> <p>Bioactivity: MI-2 is a Menin-MLL interaction inhibitor with IC₅₀ of 446±28 nM.</p> <p>Purity: 99.81%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>MI-3 (Menin-MLL inhibitor 3)</p> <p style="text-align: right;">Cat. No.: HY-15223</p> <p>Bioactivity: MI-3 is a Menin-MLL interaction inhibitor with IC50 value of 648 ± 25 nM. IC50 value: 648 ± 25 nM [1] Target: Menin-MLL in vitro: The menin-MLL inhibitors very effectively blocked proliferation of MLL-AF9 and MLL-ENL transduced BMC, with GI50 values of about 5 μM for MI-2 and MI-3. MI-2 and MI-3 showed...</p> <p>Purity: 99.63%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>MI-463</p> <p style="text-align: right;">Cat. No.: HY-19809</p> <p>Bioactivity: MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.</p> <p>Purity: 99.46%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>MI-503</p> <p style="text-align: right;">Cat. No.: HY-16925</p> <p>Bioactivity: MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.</p> <p>Purity: 98.99%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in Ethanol, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg</p> 
<p>MI-538</p> <p style="text-align: right;">Cat. No.: HY-19810</p> <p>Bioactivity: MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC₅₀ of 21 nM.</p> <p>Purity: 98.14%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>MM-102 (HMTase Inhibitor IX)</p> <p style="text-align: right;">Cat. No.: HY-12220</p> <p>Bioactivity: MM-102 is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM with an estimated Ki < 1 nM in WDR5 binding assay, which is >200 times more potent than the ARA peptide. IC50 value: 2.4 nM Target: MLL in vitro: MM-102 inhibits MLL1 methyltransferase activity and MLL-1-induced...</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 2 mg, 5 mg, 10 mg, 50 mg</p> 
<p>MM-102 TFA (HMTase Inhibitor IX (TFA))</p> <p style="text-align: right;">Cat. No.: HY-12220A</p> <p>Bioactivity: MM-102 trifluoroacetate is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM with an estimated Ki < 1 nM in WDR5 binding assay, which is >200 times more potent than the ARA peptide. IC50 value: 2.4 nM Target: MLL in vitro: MM-102 inhibits MLL1 methyltransferase activity and...</p> <p>Purity: 99.95%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg</p> 	<p>MS023</p> <p style="text-align: right;">Cat. No.: HY-19615</p> <p>Bioactivity: MS023 is a potent, selective, and cell-active inhibitor of human type I PRMTs with IC50 of 4-119 nM.</p> <p>Purity: 99.84%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 


MS049	Cat. No.: HY-100360
Bioactivity:	MS 049 is a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC ₅₀ of 34 nM and 43 nM respectively. target: PRMT4, PRMT6; IC ₅₀ : 34 nM (PRMT4), 43 nM (PRMT6); In vitro: MS 049 reduces the H3R2me2a mark in HEK293 cells in a concentration dependent manner. MS 049 treatment (72 h...
Purity:	98.0%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
	


OICR-9429	Cat. No.: HY-16993
Bioactivity:	OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction with IC ₅₀ of 5 uM. inhibit proliferation and induce differentiation .
Purity:	99.82%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
	


PFI-2 ((R)-PFI-2)	Cat. No.: HY-18627
Bioactivity:	PFI-2 is a first-in-class, potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 with IC ₅₀ of 2 nM, 500 fold active than (S)-PFI-2.
Purity:	>98%
Clinical Data:	No Development Reported
Size:	10 mg, 50 mg
	


PFI-2 hydrochloride ((R)-PFI-2 hydrochloride)	Cat. No.: HY-18627A
Bioactivity:	PFI-2 hydrochloride is a first-in-class, potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 with IC ₅₀ of 2 nM, 500 fold active than (S)-PFI-2.
Purity:	99.67%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg
	


SGC0946	Cat. No.: HY-15650
Bioactivity:	SGC0946 is a highly potent and selective DOT1L methyltransferase inhibitor with IC ₅₀ of 0.3 nM; selectively kill mixed lineage leukaemia cells.
Purity:	98.48%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
	

SGC2085	Cat. No.: HY-100565
Bioactivity:	SGC2085 is a potent and selective coactivator associated arginine methyltransferase 1 (CARM1) inhibitor with an IC₅₀ of 50 nM.
Purity:	99.10%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg
	

SGC707	Cat. No.: HY-19715
Bioactivity:	SGC707 is a first-in-class PRMT3 chemical probe which is a potent, selective, and cell-active allosteric inhibitor of PRMT3 with IC ₅₀ of 31 nM.
Purity:	98.24%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
	

UNC 0631	Cat. No.: HY-13808
Bioactivity:	UNC 0631 is a potent G9a inhibitor with IC ₅₀ value of 4 nM. IC ₅₀ value: 4 nM [1] Target: G9a UNC 0631, which had high in vitro potency versus G9a and improved lipophilicity, was highly potent (IC ₅₀ < 0.06 uM) in reducing H3K9me2 levels in MDA-MB-231 cells and had low cell toxicity. In particular,...
Purity:	98.14%
Clinical Data:	No Development Reported
Size:	5 mg, 10 mg, 25 mg, 50 mg
	

UNC 669	Cat. No.: HY-15839
Bioactivity:	UNC 669 is a potent antagonist of L3MBTL1(IC ₅₀ =4.2 uM) and L3MBTL3(IC ₅₀ =3.1 uM).
Purity:	97.42%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg
	

UNC0224	Cat. No.: HY-10929
Bioactivity:	UNC0224 is a potent and selective G9a inhibitor with IC ₅₀ of 15 nM in in the G9a Thioglo assay.
Purity:	98.0%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
	

<p>UNC0321</p> <p style="text-align: right;">Cat. No.: HY-10930</p> <p>Bioactivity: UNC0321 is a potent and selective G9a inhibitor with K_i of 63 pM, UNC0321 is the first G9a inhibitor with picomolar potency and the most potent G9a inhibitor to date.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>UNC0379</p> <p style="text-align: right;">Cat. No.: HY-12335</p> <p>Bioactivity: UNC0379 is a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8 with IC_{50} of 7.3 ± 1.0 μM; selective over 15 other methyltransferases.</p> <p>Purity: 99.95%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>UNC0379 trifluoroacetate (UNC-0379 trifluoroacetate)</p> <p style="text-align: right;">Cat. No.: HY-12335A</p> <p>Bioactivity: UNC0379 trifluoroacetate is a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8 with IC_{50} of 7.3 ± 1.0 μM; selective over 15 other methyltransferases.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>UNC0638</p> <p style="text-align: right;">Cat. No.: HY-15273</p> <p>Bioactivity: UNC0638 selectively inhibits G9a and GLP histone methyltransferase activity with IC_{50}s of less than 15 nM and 19 nM, respectively.</p> <p>Purity: 99.87%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>UNC0642</p> <p style="text-align: right;">Cat. No.: HY-13980</p> <p>Bioactivity: UNC0642 is a potent and selective G9a/GLP inhibitor, with an IC_{50} of less than 2.5 nM.</p> <p>Purity: 99.81%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>UNC0646</p> <p style="text-align: right;">Cat. No.: HY-13807</p> <p>Bioactivity: UNC0646 is a potent and selective G9a inhibitor with IC_{50} of 6 nM.</p> <p>Purity: 98.75%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p>UNC1215</p> <p style="text-align: right;">Cat. No.: HY-15649</p> <p>Bioactivity: UNC1215 is a potent and selective chemical probe for the methyllysine (Kme) reading function of L3MBTL3 with K_d value of 120 nM.</p> <p>Purity: 98.39%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>UNC1999</p> <p style="text-align: right;">Cat. No.: HY-15646</p> <p>Bioactivity: UNC1999 is a SAM-competitive, potent and selective inhibitor of EZH1/2 with IC_{50}s of 10 nM and 45 nM, respectively.</p> <p>Purity: 99.47%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>UNC3866</p> <p style="text-align: right;">Cat. No.: HY-100832</p> <p>Bioactivity: UNC3866 is a potent antagonist of the CBX7-H3 interaction as determined by AlphaScreen (IC_{50}=66 ± 1.2 nM) and is more than 100-fold selective for CBX7 over the other nine members of this methyl-lysine (Kme) reader panel.</p> <p>Purity: 98.30%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>WDR5-0103 (WD-Repeat Protein 5-0103)</p> <p style="text-align: right;">Cat. No.: HY-19347</p> <p>Bioactivity: WDR5-0103 is a potent and selective WD repeat-containing protein 5 (WDR5) antagonist with K_d of 450 nM.</p> <p>Purity: 97.40%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 

XY1


Cat. No.: HY-19714

Bioactivity: XY1 is a very close analogue of SGC707 (a potent, selective, and non-competitive inhibitor of PRMT3 with IC50 of 31 nM), but XY1 is completely inactive.

Purity: 98.04%

Clinical Data: No Development Reported


Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



JAK

Janus kinase

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)

Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Since members of the type I and type II cytokine receptor families possess no catalytic kinase activity, they rely on the JAK family of tyrosine kinases to phosphorylate and activate downstream proteins involved in their signal transduction pathways. The receptors exist as paired polypeptides, thus exhibiting two intracellular signal-transducing domains. JAKs associate with a proline-rich region in each intracellular domain, which is adjacent to the cell membrane and called a box1/box2 region. After the receptor associates with its respective cytokine/ligand, it goes through a conformational change,

bringing the two JAKs close enough to phosphorylate each other. The JAK autophosphorylation induces a conformational change within itself, enabling it to transduce the intracellular signal by further phosphorylating and activating transcription factors called STATs. The activated STATs dissociate from the receptor and form dimers before translocating to the cell nucleus, where they regulate transcription of selected genes.

JAK Inhibitors & Modulators

<p>(3R,4S)-Tofacitinib</p> <p style="text-align: right;">Cat. No.: HY-40354D</p> <p>Bioactivity: (3R,4S)-Tofacitinib is an enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC₅₀ of 1 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg</p> 	<p>(3S,4R)-Tofacitinib</p> <p style="text-align: right;">Cat. No.: HY-40354B</p> <p>Bioactivity: (3S,4R)-Tofacitinib is an enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC₅₀ of 1 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg</p> 
<p>(3S,4S)-Tofacitinib</p> <p style="text-align: right;">Cat. No.: HY-40354C</p> <p>Bioactivity: (3S,4S)-Tofacitinib is the S-enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC₅₀ of 1 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg</p> 	<p>ASN-002</p> <p style="text-align: right;">Cat. No.: HY-103018</p> <p>Bioactivity: ASN-002 is a potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC₅₀ values of 5-46 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p> 
<p>AT9283</p> <p style="text-align: right;">Cat. No.: HY-50514</p> <p>Bioactivity: AT9283 is a multi-targeted inhibitor with IC₅₀s of 1.2 nM, 1.1 nM for JAK2 and JAK3, respectively, and is also potent to Aurora A, Aurora B and Abl(T315I).</p> <p>Purity: 99.13%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>AZ960</p> <p style="text-align: right;">Cat. No.: HY-10411</p> <p>Bioactivity: AZ960 is a potent and specific inhibitor of the JAK2 kinase with a K_i of 0.45 nM.</p> <p>Purity: 98.04%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 2 mg, 5 mg, 10 mg, 50 mg</p> 
<p>AZD-1480 (AZD1480; AZD 1480)</p> <p style="text-align: right;">Cat. No.: HY-10193</p> <p>Bioactivity: AZD-1480 is a novel ATP-competitive JAK2 inhibitor with IC₅₀ of < 0.4 nM, selectively against JAK3 and Tyk2, and to a smaller extent against JAK1.</p> <p>Purity: 99.37%</p> <p>Clinical Data: Phase 1</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>AZD-4205</p> <p style="text-align: right;">Cat. No.: HY-107361</p> <p>Bioactivity: AZD-4205 is a selective JAK1 inhibitor, with an IC₅₀ of 73 nM, weakly inhibits JAK2, and shows little inhibition on JAK3 (IC₅₀ >14.7, >30 μM, respectively).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p> 
<p>Baricitinib (INC028050; LY3009104)</p> <p style="text-align: right;">Cat. No.: HY-15315</p> <p>Bioactivity: Baricitinib is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC₅₀s of 5.9 nM and 5.7 nM, respectively.</p> <p>Purity: 99.70%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</p> 	<p>Baricitinib phosphate (INC028050; LY3009104)</p> <p style="text-align: right;">Cat. No.: HY-15315A</p> <p>Bioactivity: Baricitinib phosphate is a selective orally bioavailable JAK1/ JAK2 inhibitor with IC₅₀ of 5.9 nM and 5.7 nM, respectively.</p> <p>Purity: 99.49%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 

<p>BMS-066</p> <p style="text-align: right;">Cat. No.: HY-18710</p> <p>Bioactivity: BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor, with IC₅₀s of 9 nM and 72 nM, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p> 	<p>BMS-911543</p> <p style="text-align: right;">Cat. No.: HY-15270</p> <p>Bioactivity: BMS-911543 is a selective JAK2 inhibitor, with IC₅₀s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (IC₅₀, 75, 360, 66 nM, respectively).</p> <p>Purity: 98.03%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>CEP-33779</p> <p style="text-align: right;">Cat. No.: HY-15343</p> <p>Bioactivity: CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC₅₀ of 1.8±0.6 nM.</p> <p>Purity: 98.04%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Cerdulatinib (PRT062070; PRT2070)</p> <p style="text-align: right;">Cat. No.: HY-15999</p> <p>Bioactivity: Cerdulatinib (PRT062070) is a dual JAK and SYK inhibitor with IC₅₀s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.</p> <p>Purity: 99.00%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 
<p>CHZ868</p> <p style="text-align: right;">Cat. No.: HY-18960</p> <p>Bioactivity: CHZ868 is a type II JAK2 inhibitor with an IC₅₀ of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.</p> <p>Purity: 98.33%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>Cucurbitacin I (Elatericin B; JSI-124; NSC-521777)</p> <p style="text-align: right;">Cat. No.: HY-N1405</p> <p>Bioactivity: Cucurbitacin I is a natural selective inhibitor of JAK2/STAT3, with potent anti-cancer activity.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg</p> 
<p>CYT387 (momelotinib)</p> <p style="text-align: right;">Cat. No.: HY-10961</p> <p>Bioactivity: CYT387 is an ATP-competitive inhibitor of JAK1/JAK2 with IC₅₀a of 11 nM and 18 nM, respectively. CYT387 shows much less activity against JAK3.</p> <p>Purity: 98.11%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>CYT387 Mesylate (momelotinib Mesylate)</p> <p style="text-align: right;">Cat. No.: HY-10963</p> <p>Bioactivity: CYT387 Mesylate is an ATP-competitive inhibitor of JAK1/JAK2 with IC₅₀ of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.</p> <p>Purity: >98%</p> <p>Clinical Data: Phase 3</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>CYT387 sulfate salt (momelotinib sulfate)</p> <p style="text-align: right;">Cat. No.: HY-10962</p> <p>Bioactivity: CYT387 sulfate salt is an ATP-competitive inhibitor of JAK1/JAK2 with IC₅₀ of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC₅₀=155 nM).</p> <p>Purity: 96.0%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Decernotinib (VX-509; VRT-831509)</p> <p style="text-align: right;">Cat. No.: HY-12469</p> <p>Bioactivity: Decernotinib is a potent, orally active JAK3 inhibitor, with K_is of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively.</p> <p>Purity: 98.91%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg</p> 

<p>Delgocitinib (JTE-052) Cat. No.: HY-109053</p> <p>Bioactivity: Delgocitinib is a novel and specific JAK inhibitor with IC₅₀s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.</p> <p>Purity: 99.14% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>Fedratinib (TG-101348; SAR 302503) Cat. No.: HY-10409</p> <p>Bioactivity: TG-101348 is a selective inhibitor of JAK2 with an IC₅₀ of 3 nM, showing 35- and 334-fold selectivity over JAK1 and JAK3, respectively.</p> <p>Purity: 98.62% Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>FM381 Cat. No.: HY-102046</p> <p>Bioactivity: FM381 is a potent covalent reversible inhibitor of JAK3 targeting the unique Cys909 at the gatekeeper position +7 in JAK3. FM-381 has an IC₅₀ of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively.</p> <p>Purity: 98.41% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>GLPG0634 (Filgotinib) Cat. No.: HY-18300</p> <p>Bioactivity: GLPG0634 is a selective JAK1 inhibitor with IC₅₀ of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.</p> <p>Purity: 99.64% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>GLPG0634 analog Cat. No.: HY-13961</p> <p>Bioactivity: GLPG0634 (analog) (compound176) is a pan JAK inhibitor with IC₅₀s of 50-200 nM for JAK1/JAK2/JAK3; more information can be found in the reference patents.</p> <p>Purity: 98.00% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg</p> 	<p>Itacitinib (INC8039110) Cat. No.: HY-16997</p> <p>Bioactivity: Itacitinib is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis.</p> <p>Purity: 99.87% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 
<p>Itacitinib adipate Cat. No.: HY-16997A</p> <p>Bioactivity: Itacitinib adipate is a selective JAK1 inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis.</p> <p>Purity: 98.78% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>JAK inhibitor 1 Cat. No.: HY-111471</p> <p>Bioactivity: JAK inhibitor 1 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p> 
<p>JAK-IN-1 Cat. No.: HY-13827</p> <p>Bioactivity: JAK-IN-1 is a JAK1/2/3 inhibitor with IC₅₀s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p> 	<p>JAK3-IN-1 Cat. No.: HY-19544</p> <p>Bioactivity: JAK3-IN-1 is a potent JAK3 inhibitor with IC₅₀ of 4.8 nM, also inhibits JAK1 (IC₅₀ = 896 nM) and JAK2 (IC₅₀ = 1050 nM). IC₅₀ value: 4.8 nM [1] Target: JAK3 in vitro: JAK3-IN-1 provides a set of useful tools to pharmacologically interrogate JAK3-dependent biology. JAK3-IN-1 completely inhibits IL-4...</p> <p>Purity: 99.16% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 

<p>JAK3-IN-6</p> <p style="text-align: right;">Cat. No.: HY-101976</p> <p>Bioactivity: JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC₅₀ of 0.15 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p> 	<p>JAK3-IN-7</p> <p style="text-align: right;">Cat. No.: HY-U00390</p> <p>Bioactivity: JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC₅₀ of <0.01 μM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg</p> 
<p>JANEX-1 (WHI-P131)</p> <p style="text-align: right;">Cat. No.: HY-15508</p> <p>Bioactivity: JANEX-1 is a potent and specific JAK3 inhibitor (estimated K_i=2.3 μM). JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC₅₀ of 78 μM), does not inhibit JAK1 and JAK2.</p> <p>Purity: 99.84%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>LFM-A13</p> <p style="text-align: right;">Cat. No.: HY-18009</p> <p>Bioactivity: LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.</p> <p>Purity: 99.70%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p>LY2784544 (gandotinib)</p> <p style="text-align: right;">Cat. No.: HY-13034</p> <p>Bioactivity: LY2784544 is a potent JAK2 inhibitor with IC₅₀ of 3 nM. LY2784544 also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC₅₀ of 4, 25, 32, 44, and 95 nM.</p> <p>Purity: 99.96%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>NS-018</p> <p style="text-align: right;">Cat. No.: HY-19631A</p> <p>Bioactivity: NS-018 is a highly active and orally bioavailable JAK2 inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀ 33 nM), JAK3 (IC₅₀ 39 nM), and Tyk2 (IC₅₀ 22 nM).</p> <p>Purity: >98%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>NS-018 hydrochloride (NS018 hydrochloride; NS 018 hydrochloride)</p> <p style="text-align: right;">Cat. No.: HY-19631B</p> <p>Bioactivity: NS-018 hydrochloride is a highly active and orally bioavailable JAK2 inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀ 33 nM), JAK3 (IC₅₀ 39 nM), and Tyk2 (IC₅₀ 22 nM).</p> <p>Purity: >98%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>NS-018 maleate</p> <p style="text-align: right;">Cat. No.: HY-19631</p> <p>Bioactivity: NS-018 maleate is a highly active and orally bioavailable JAK2 inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀ 33 nM), JAK3 (IC₅₀ 39 nM), and Tyk2 (IC₅₀ 22 nM).</p> <p>Purity: 98.33%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>NSC 42834 (Z3)</p> <p style="text-align: right;">Cat. No.: HY-15480</p> <p>Bioactivity: NSC 42834(JAK2 Inhibitor V, Z3), a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity. IC50 value: Target: Jak2; Jak2-V617F Z3 selectively inhibited Jak2 kinase...</p> <p>Purity: 95.5%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg</p> 	<p>NVP-BSK805 (BSK 805)</p> <p style="text-align: right;">Cat. No.: HY-14722</p> <p>Bioactivity: NVP-BSK805 is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 


NVP-BSK805 dihydrochloride
(BSK805 dihydrochloride) Cat. No.: HY-14722A

Bioactivity: NVP-BSK805 dihydrochloride is an ATP-competitive **JAK2** inhibitor, with **IC₅₀**s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.

Purity: 98.00%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg




Oclacitinib maleate
(PF-03394197 maleate) Cat. No.: HY-13577A

Bioactivity: Oclacitinib maleate is a novel **JAK** inhibitor. Oclacitinib is most potent at inhibiting **JAK1** (**IC₅₀**=10 nM).

Purity: 99.53%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg




Pacritinib
(SB1518) Cat. No.: HY-16379

Bioactivity: Pacritinib is a potent inhibitor of both wild-type **JAK2** (**IC₅₀**=23 nM) and **JAK2^{V617F}** mutant (**IC₅₀**=19 nM). Pacritinib also inhibits **FLT3** (**IC₅₀**=22 nM) and its mutant **FLT3^{D835Y}** (**IC₅₀**=6 nM).

Purity: 99.66%

Clinical Data: Phase 3

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg




Peficitinib
(ASP015K; JNJ-54781532) Cat. No.: HY-19568

Bioactivity: Peficitinib is an oral **JAK** inhibitor, with **IC₅₀**s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.

Purity: 99.43%

Clinical Data: Phase 3

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg




PF-06651600 Cat. No.: HY-100754

Bioactivity: PF-06651600 is a potent **JAK3**-selective inhibitor with an **IC₅₀** of 33.1 nM.

Purity: 99.98%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg




Pyridone 6
(CMP 6; JAK Inhibitor) Cat. No.: HY-14435

Bioactivity: Pyridone 6 is a **pan-JAK** inhibitor, which potently inhibits the JAK kinase family, with **IC₅₀**s of 1 nM for **JAK2** and **TYK2**, 5 nM for **JAK3**, and 15 nM for **JAK1**, while displaying significantly weaker affinities (130 nM to >10 nM) for other protein tyrosine kinases.

Purity: 98.04%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg




RGB-286638 Cat. No.: HY-15504

Bioactivity: RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with **IC₅₀**s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3 β , TA...

Purity: >98%

Clinical Data: Phase 1

Size: 5 mg, 10 mg, 50 mg, 100 mg




RGB-286638 free base Cat. No.: HY-15504A

Bioactivity: RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with **IC₅₀**s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3 β , TA...

Purity: 99.55%

Clinical Data: Phase 1

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg




Ruxolitinib
(INCB018424) Cat. No.: HY-50856

Bioactivity: Ruxolitinib is a potent and selective **JAK1/2** inhibitor with **IC₅₀**s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3.

Purity: 99.99%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g




Ruxolitinib phosphate
(INCB018424 phosphate) Cat. No.: HY-50858

Bioactivity: Ruxolitinib phosphate is a potent **JAK1/2** inhibitor with **IC₅₀**s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.









Purity: 99.89%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g




<p>Ruxolitinib S enantiomer (S-Ruxolitinib; INCB18424) Cat. No.: HY-50856A</p> <p>Bioactivity: Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC₅₀ of 3.3 nM/2.8 nM in cell-free assays.</p> <p>Purity: 99.88%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg</p> 	<p>Ruxolitinib sulfate (INCB018424 sulfate) Cat. No.: HY-50859</p> <p>Bioactivity: Ruxolitinib sulfate is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC₅₀s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.</p> <p>Purity: >98%</p> <p>Clinical Data: Launched</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>SAR-20347 Cat. No.: HY-100895</p> <p>Bioactivity: SAR-20347 is an inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC₅₀s of 0.6, 23, 26 and 41 nM, respectively.</p> <p>Purity: 97.00%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>SB1317 (TG02) Cat. No.: HY-15166</p> <p>Bioactivity: SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 for the treatment of cancer, with IC₅₀ of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively.</p> <p>Purity: 99.85%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Solcitinib (GSK-2586184; GLPG-0778) Cat. No.: HY-16755</p> <p>Bioactivity: Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC₅₀ of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.</p> <p>Purity: 99.42%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>TG101209 Cat. No.: HY-10410</p> <p>Bioactivity: TG101209 is a selective JAK2 inhibitor with IC₅₀ of 6 nM, less potent to Flt3 and RET with IC₅₀ of 25 nM and 17 nM, approx 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.</p> <p>Purity: 98.94%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Tofacitinib (Tasocitinib; CP-690550) Cat. No.: HY-40354</p> <p>Bioactivity: Tofacitinib is a JAK1/2/3 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.</p> <p>Purity: 99.96%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</p> 	<p>Tofacitinib citrate (Tasocitinib citrate; CP-690550 citrate) Cat. No.: HY-40354A</p> <p>Bioactivity: Tofacitinib citrate is a JAK1/2/3 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.</p> <p>Purity: 99.92%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</p> 
<p>TYK2-IN-2 Cat. No.: HY-101762</p> <p>Bioactivity: TYK2-IN-2 is an inhibitor of TYK2, used for treatment of inflammatory and autoimmune diseases.</p> <p>Purity: 99.41%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Tyk2-IN-3 Cat. No.: HY-18709</p> <p>Bioactivity: Tyk2-IN-3 is a Tyk2 pseudokinase inhibitor, with an IC₅₀ of 485 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p> 

<p>Tyk2-IN-4</p> <p style="text-align: right;">Cat. No.: HY-117287</p> <p>Bioactivity: Tyk2-IN-4 is a selective, potent, allosteric inhibitor of tyrosine kinase 2 (Tyk2).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p> 	<p>Upadacitinib (ABT-494)</p> <p style="text-align: right;">Cat. No.: HY-19569</p> <p>Bioactivity: Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC₅₀ of 43 nM, being developed for the treatment of several autoimmune disorders.</p> <p>Purity: 99.96%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 5 g, 10 g</p> 
<p>WHI-P154</p> <p style="text-align: right;">Cat. No.: HY-13895</p> <p>Bioactivity: WHI-P154 is a potent EGFR inhibitor, and also modestly blocks JAK3, with IC₅₀s of 4 nM and 1.8 μM, respectively.</p> <p>Purity: 98.14%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 	<p>WHI-P97</p> <p style="text-align: right;">Cat. No.: HY-11067</p> <p>Bioactivity: WHI-P97 is a rationally designed potent inhibitor of JAK-3. IC50 value: Target: JAK3 Treatment of mast cells with WHI-P97 inhibited the translocation of 5-lipoxygenase (5-LO) from the nucleoplasm to the nuclear membrane and consequently 5-LO-dependent leukotriene (LT) synthesis after IgE...</p> <p>Purity: 99.48%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>WP1066</p> <p style="text-align: right;">Cat. No.: HY-15312</p> <p>Bioactivity: WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.</p> <p>Purity: 99.67%</p> <p>Clinical Data: Phase 1</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 	<p>XL019</p> <p style="text-align: right;">Cat. No.: HY-13775</p> <p>Bioactivity: XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1; shows good biochemical and cellular potency against JAK2 with good selectivity against the Janus Kinase family as well as a broad kinase panel. IC50 Value: 2.2 nM (JAK2); 214.2 nM (JAK3) [1] XL019...</p> <p>Purity: 98.0%</p> <p>Clinical Data: Phase 1</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>ZM39923</p> <p style="text-align: right;">Cat. No.: HY-12589A</p> <p>Bioactivity: ZM39923 is a JAK3 inhibitor, with a pIC₅₀ of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC₅₀ of 10 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mg, 50 mg</p> 	<p>ZM39923 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-12589</p> <p>Bioactivity: ZM39923 hydrochloride is a JAK3 inhibitor, with a pIC₅₀ of 7.1; ZM39923 hydrochloride also potently inhibits tissue transglutaminase (TGM2) with an IC₅₀ of 10 nM.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 

MicroRNA

miRNA

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)

MiRNAs are 21-25 nucleotide RNAs that negatively regulate gene expression through translational repression or cleavage of a target mRNA. They are transcribed as precursors that are processed by the nucleases Drosha and Dicer.

Small molecules targeting the secondary structure of precursor miRNAs can be more selective modulators of function than oligonucleotides that target RNA sequence.

MicroRNAs (miRNAs) and promoter hypermethylation are vital epigenetic mechanisms for transcriptional inactivation of tumor suppressor.


MicroRNA Inhibitors & Modulators

Lin28-let-7a antagonist 1

Cat. No.: HY-100692

Bioactivity: Lin28-let-7a antagonist 1 shows a clear antagonistic effect against the **Lin28-let-7a interaction** with an **IC₅₀** of 4.03 μ M for Lin28A-let-7a-1 interaction.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



MIR96-IN-1

Cat. No.: HY-15843

Bioactivity: MIR96-IN-1 selectively inhibits biogenesis of microRNA-96, upregulating a protein target (FOXO1) and inducing apoptosis in cancer cells. Target: microRNA-96 in vitro: MIR96-IN-1 inhibits biogenesis of its target precursor miRNA to varying extents : MIR96-IN-1 reduces the expression level of miR-96 by...

Purity: 99.30%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 1 mg, 5 mg, 10 mg, 50 mg, 100 mg




SID 3712249

(MiR-544 Inhibitor 1)

Cat. No.: HY-19731

Bioactivity: SID 3712249 (MiR-544 Inhibitor 1) is an inhibitor of the biogenesis of microRNA-544 (miR-544).

Purity: 99.84%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Targapremir-210

Cat. No.: HY-15861

Bioactivity: Targapremir-210 is a potent **miR-210** inhibitor with an **IC₅₀** of 200 nM in MDA-MB-231 cells. Targapremir-210 binds to the Dicer site of the miR-210 hairpin precursor. This interaction inhibits production of the mature miRNA.


Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



PARP

poly ADP ribose polymerase

HDAC Inhibitor:
Vorinostat (SAHA)













HDAC (Histone deacetylase)

PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death. The PARP family comprises 17 members. They have all very different structures and functions in the cell. PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2) have a confirmed PARP activity. Others include PARP3, PARP6, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. PARP is found in the cell's nucleus. The main role is to detect and signal single-strand DNA breaks (SSB) to the enzymatic machinery involved in the SSB repair.

PARP Inhibitors & Modulators

<p>A-966492</p> <p style="text-align: right;">Cat. No.: HY-10614</p> <p>Bioactivity: A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.</p> <p>Purity: 98.59%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>AG14361</p> <p style="text-align: right;">Cat. No.: HY-12032</p> <p>Bioactivity: AG14361 is a potent PARP-1 inhibitor, with a K_i of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC₅₀s are 29 nM and 14 nM, respectively.</p> <p>Purity: 99.41%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>AZ6102</p> <p style="text-align: right;">Cat. No.: HY-12975</p> <p>Bioactivity: AZ6102 is a potent dual TNKS1 and TNKS2 inhibitor, with IC₅₀s of 3 nM and 1 nM, respectively, and also has 100-fold selectivity against other PARP family enzymes, with IC₅₀s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PAR...</p> <p>Purity: 99.65%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>AZD-2461</p> <p style="text-align: right;">Cat. No.: HY-13536</p> <p>Bioactivity: AZD-2461 is a potent PARP inhibitor, with IC₅₀s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.</p> <p>Purity: 98.39%</p> <p>Clinical Data: Phase 1</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>BGP-15</p> <p style="text-align: right;">Cat. No.: HY-100828</p> <p>Bioactivity: BGP-15 is a PARP inhibitor, with an IC₅₀ and a K_i of 120 and 57 μM, respectively.</p> <p>Purity: 98.0%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>BMN-673 (Talazoparib; LT-673)</p> <p style="text-align: right;">Cat. No.: HY-16106</p> <p>Bioactivity: BMN-673 (Talazoparib) is a highly potent PARP1/2 inhibitor with K_is of 1.2 nM and 0.87 nM, respectively.</p> <p>Purity: 99.83%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 
<p>BMN-673 8R,9S (Talazoparib (8R,9S); (8R,9S)-LT-673)</p> <p style="text-align: right;">Cat. No.: HY-16106A</p> <p>Bioactivity: BMN-673 8R,9S is an enantiomer of BMN-673, less active than BMN-673 on the inhibition of PARP1, with an IC₅₀ of 144 nM.</p> <p>Purity: 95.08%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>BRCA1-IN-1</p> <p style="text-align: right;">Cat. No.: HY-100863</p> <p>Bioactivity: BRCA1-IN-1 is a novel small-molecule-like BRCA1 inhibitor with IC₅₀ and K_i of 0.53 μM and 0.71 μM, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 250 mg, 500 mg</p> 
<p>BSI-201 (Iniparib; NSC-746045; IND-71677)</p> <p style="text-align: right;">Cat. No.: HY-12015</p> <p>Bioactivity: BSI-201 is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.</p> <p>Purity: 99.65%</p> <p>Clinical Data: Phase 3</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</p> 	<p>E7449</p> <p style="text-align: right;">Cat. No.: HY-12418</p> <p>Bioactivity: E7449 is a potent PARP1 and PARP2 inhibitor and also inhibits TNKS1 and TNKS2, with IC₅₀s of 2.0, 1.0, 50 and 50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using ³²P-NAD⁺ as substrate.</p> <p>Purity: 99.0%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 

<p>G007-LK</p> <p style="text-align: right;">Cat. No.: HY-12438</p> <p>Bioactivity: G007-LK is a potent and selective inhibitor of TNKS1 and TNKS2, with IC₅₀s of 46 nM and 25 nM, respectively.</p> <p>Purity: 99.24%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>INO-1001 (3-Aminobenzamide)</p> <p style="text-align: right;">Cat. No.: HY-12022</p> <p>Bioactivity: INO-1001 is a potent inhibitor of PARP with IC₅₀ of appr 50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.</p> <p>Purity: 99.92%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 200 mg, 500 mg</p> 
<p>JW 55</p> <p style="text-align: right;">Cat. No.: HY-13968</p> <p>Bioactivity: JW 55 is a potent and selective β-catenin signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with IC₅₀s of 1.9 μM and 830 nM respectively.</p> <p>Purity: 99.10%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 	<p>K-756</p> <p style="text-align: right;">Cat. No.: HY-U00422</p> <p>Bioactivity: K-756 is a direct and selective tankyrase (TNKS) inhibitor, which inhibits the ADP-ribosylation activity of TNKS1 and TNKS2 with IC₅₀s of 31 and 36 nM, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg</p> 
<p>ME0328</p> <p style="text-align: right;">Cat. No.: HY-100225</p> <p>Bioactivity: ME0328 is a potent and selective ARTD3/ PARP3 inhibitor with an IC₅₀ of 0.89±0.28 μM.</p> <p>Purity: 99.34%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>MN-64</p> <p style="text-align: right;">Cat. No.: HY-19351</p> <p>Bioactivity: MN-64 is a potent tankyrase 1 inhibitor, with IC₅₀s of 6 nM, 72 nM, 19.1 μM, and 39.4 μM for TNKS1, TNKS2, ARTD1 and ARTD2, respectively.</p> <p>Purity: 98.22%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Niraparib (MK-4827)</p> <p style="text-align: right;">Cat. No.: HY-10619</p> <p>Bioactivity: MK-4827 (Niraparib) is a highly potent PARP1 and PARP2 inhibitor with IC₅₀s of 3.8 and 2.1 nM, respectively.</p> <p>Purity: 99.88%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Niraparib hydrochloride (MK-4827 (hydrochloride))</p> <p style="text-align: right;">Cat. No.: HY-10619A</p> <p>Bioactivity: MK-4827 hydrochloride is an excellent PARP1 and PARP2 inhibitor with IC₅₀ of 3.8 and 2.1 nM, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: Launched</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Niraparib R-enantiomer (MK 4827 (R-enantiomer))</p> <p style="text-align: right;">Cat. No.: HY-10619D</p> <p>Bioactivity: MK-4827 R-enantiomer is an excellent PARP1 inhibitor with IC₅₀ of 2.4 nM.</p> <p>Purity: 98.58%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>Niraparib tosylate (MK-4827 (tosylate))</p> <p style="text-align: right;">Cat. No.: HY-10619B</p> <p>Bioactivity: MK-4827 tosylate is an excellent PARP1 and PARP2 inhibitor with an IC₅₀ of 3.8 and 2.1 nM, respectively.</p> <p>Purity: 99.52%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 

<p>NMS-P118 Cat. No.: HY-18954</p> <p>Bioactivity: NMS-P118 is a potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy.</p> <p>Purity: 99.08% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>NVP-TNKS656 (TNKS656) Cat. No.: HY-13990</p> <p>Bioactivity: NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC₅₀ of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.</p> <p>Purity: 99.14% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>Olaparib (AZD2281; KU0059436) Cat. No.: HY-10162</p> <p>Bioactivity: Olaparib (AZD2281;KU0059436) is a potent and oral PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively.</p> <p>Purity: 99.71% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g</p> 	<p>Pamiparib (BGB-290) Cat. No.: HY-104044</p> <p>Bioactivity: Pamiparib is a PARP inhibitor which can be used for the treatment of various cancers including the solid tumor, extracted from patent WO 2013097225 A1.</p> <p>Purity: 99.97% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>PJ34 Cat. No.: HY-13688A</p> <p>Bioactivity: PJ34 is a potent specific inhibitor of PARP1/ 2 with IC₅₀ of 110 nM and 86 nM, respectively.</p> <p>Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 	<p>PJ34 hydrochloride Cat. No.: HY-13688</p> <p>Bioactivity: PJ34 hydrochloride is a potent specific inhibitor of PARP1/ 2 with IC₅₀ of 110 nM and 86 nM, respectively.</p> <p>Purity: 97.09% Clinical Data: No Development Reported Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg</p> 
<p>Rucaparib (AG014699; PF-01367338) Cat. No.: HY-10617A</p> <p>Bioactivity: Rucaparib is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP domains.</p> <p>Purity: >98% Clinical Data: Launched Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Rucaparib Camsylate Cat. No.: HY-102003</p> <p>Bioactivity: Rucaparib is an inhibitor of PARP with a K_i of 1.4 nM for PARP1, and also shows binding affinity to eight other PARP domains.</p> <p>Purity: 99.30% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Rucaparib phosphate (AG-014699 phosphate; PF-01367338 phosphate) Cat. No.: HY-10617</p> <p>Bioactivity: Rucaparib (AG-014699, PF-01367338) is a potent and oral PARP1/2/3 inhibitor, with a K_i of 1.4 nM for PARP1 in cell-free assay, also showing binding affinity to eight other PARP domains.</p> <p>Purity: 99.89% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p> 	<p>Talazoparib tosylate (BMN 673ts) Cat. No.: HY-108413</p> <p>Bioactivity: Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC₅₀ of 0.57 nM for PARP1.</p> <p>Purity: 99.74% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 


UPF 1069 Cat. No.: HY-14478

Bioactivity: UPF 1069 is a **PARP** inhibitor, with **IC₅₀s** of 8 and 0.3 μ M for PARP-1 and PARP-2, respectively.

Purity: 98.88%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
10 mg, 50 mg




Veliparib (ABT-888) Cat. No.: HY-10129

Bioactivity: Veliparib is a potent **PARP** inhibitor, inhibiting **PARP1** and **PARP2** with **K_is** of 5.2 and 2.9 nM, respectively.

Purity: 98.0%

Clinical Data: Phase 3

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg




Veliparib dihydrochloride (ABT-888 dihydrochloride) Cat. No.: HY-10130

Bioactivity: Veliparib (dihydrochloride) is a potent inhibitor of **PARP1** and **PARP2** with **K_is** of 5.2 nM and 2.9 nM in cell-free assays, respectively.

Purity: 99.62%

Clinical Data: Phase 3

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg




WD2000-012547 Cat. No.: HY-U00223

Bioactivity: WD2000-012547 is a selective poly(ADP-ribose)-polymerase (PARP-1) inhibitor with a **pK_i** of 8.221.

Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg, 10 mg, 20 mg




XAV-939 Cat. No.: HY-15147

Bioactivity: XAV-939 is a **tankyrase (TNKS)** inhibitor and an indirect inhibitor of **Wnt/ β -catenin signaling**, with **IC₅₀s** of 5 and 2 nM for TNKS1 and TNKS2, respectively.

Purity: 98.04%

Clinical Data: No Development Reported


Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



PKC

Protein kinase C

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)

PKC (Protein kinase C) is a family of protein kinase enzymes that are involved in controlling the function of other proteins through the phosphorylation of hydroxyl groups of serine and threonine amino acid residues on these proteins. PKC enzymes in turn are activated by signals such as increases in the concentration of diacylglycerol (DAG) or calcium ions (Ca^{2+}). Hence PKC enzymes play important roles in several signal transduction cascades. The PKC family consists of 15 isozymes in humans: PKC- α (PRKCA), PKC- β 1 (PRKCB), PKC- β 2 (PRKCB), PKC- γ (PRKCG), PKC- δ (PRKCD), PKC- δ 1 (PRKD1), PKC- δ 2 (PRKD2), PKC- δ 3 (PRKD3), PKC- ϵ (PRKCE), PKC- η (PRKCH), PKC- θ (PRKCQ), PKC- ι (PRKCI), PKC- ζ (PRKCZ), PK-N1 (PKN1), PK-N2 (PKN2),

PK-N3 (PKN3). PKC is involved in receptor desensitization, in modulating membrane structure events, in regulating transcription, in mediating immune responses, in regulating cell growth, and in learning and memory. These functions are achieved by PKC-mediated phosphorylation of other proteins.

PKC Inhibitors & Modulators

(-)-Indolactam V

(Indolactam V)


Cat. No.: HY-12307

Bioactivity: (-)-Indolactam V is a **PKC** activator, with $K_{1/2}$ s of 3.36 nM, 1.03 μ M for η -CRD2 (PKC η surrogate peptide), γ -CRD2 (PKC γ surrogate peptide), and $K_{1/2}$ s of 5.5 nM (η -C1B), 7.7 nM (ϵ -C1B), 8.3 nM (δ -C1B), 18.9 nM (β -C1A-long), 20.8...

Purity: 99.18%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



AS2521780


Cat. No.: HY-12663

Bioactivity: AS2521780 is a novel **PKC θ** selective inhibitor with an IC_{50} of 0.48 nM.

Purity: >98%

Clinical Data: No Development Reported

Size: 250 mg, 500 mg



Bisindolylmaleimide I

(GF109203X; Go 6850)


Cat. No.: HY-13867

Bioactivity: Bisindolylmaleimide I (GF109203X) is a highly selective, cell-permeable, and reversible protein kinase C (**PKC**) inhibitor with a K_i of 14 nM.

Purity: 98.04%

Clinical Data: Launched

Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg



CGP60474


Cat. No.: HY-11009

Bioactivity: CGP60474 is a potent **VEGFR-2** inhibitor, with an IC_{50} of 84 nM, and also an ATP-competitive **PKC** inhibitor.

Purity: 99.88%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Chelerythrine Chloride


Cat. No.: HY-12048

Bioactivity: Chelerythrine Chloride is a potent, cell-permeable inhibitor of **protein kinase C**, with an IC_{50} of 660 nM, competitive with respect to the phosphate acceptor and non-competitive with respect to ATP.

Purity: 98.0%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



D-erythro-Sphingosine (Erythrosphingosine; erythro-C18-Sphingosine; trans-4-Sphingenine)


Cat. No.: HY-101047

Bioactivity: D-erythro-Sphingosine is a very potent activator of **p32-kinase** with an EC_{50} of 8 μ M. D-erythro-Sphingosine inhibits protein kinase C (**PKC**).

Purity: >98%

Clinical Data: No Development Reported

Size: 250 mg, 500 mg



Delcasertib

(KAI-9803; BMS-875944)

Cat. No.: HY-106262

Bioactivity: KAI-9803 is a potent and selective δ -protein kinase C (**δ PKC**) inhibitor.

Purity: 95.38%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg



Enzastaurin

(LY317615)


Cat. No.: HY-10342

Bioactivity: Enzastaurin is a potent and selective **PKC β** inhibitor with an IC_{50} of 6 nM, showing 6- to 20-fold selectivity over PKC α , PKC γ and PKC ϵ .

Purity: 99.84%

Clinical Data: Phase 3

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Go 6983

(Gö 6983; Goe 6983)


Cat. No.: HY-13689

Bioactivity: Go 6983 is a pan-PKC inhibitor against for **PKC α** , **PKC β** , **PKC γ** , **PKC δ** and **PKC ζ** with IC_{50} of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.

Purity: 98.0%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



HA-100


Cat. No.: HY-100984

Bioactivity: HA-100 is an inhibitor of cGMP-dependent protein kinase (**PKG**), cAMP-dependent protein kinase (**PKA**), Protein kinase C (**PKC**) and **MLC-kinase** with IC_{50} s of 4, 8, 12 and 240 μ M, respectively.


Purity: 99.76%


Clinical Data: No Development Reported


Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg





<p>Ingenol (-)-Ingenol) Cat. No.: HY-N0865</p> <p>Bioactivity: Ingenol is a PKC activator, with a K_i of 30 μM, with antitumor activity.</p> <p>Purity: 99.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 	<p>Ingenol Mebutate (Ingenol 3-angelate; PEP005) Cat. No.: HY-B0719</p> <p>Bioactivity: Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent PKC modulator, with K_is of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ϵ, respectively, and has antiinflammatory and antitumor activity.</p> <p>Purity: 98.74%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg</p> 
<p>LXS196 Cat. No.: HY-101569</p> <p>Bioactivity: LXS196 is a potent and orally active protein kinase C (PKC) inhibitor under Phase I clinical trials for the treatment of uveal melanoma.</p> <p>Purity: 99.25%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Midostaurin (CGP41231; PKC412; CGP 41251) Cat. No.: HY-10230</p> <p>Bioactivity: PKC412 is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC_{50} ranging from 16-500 nM.</p> <p>Purity: 98.60%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Mitoxantrone (mitozantrone) Cat. No.: HY-13502</p> <p>Bioactivity: Mitoxantrone is a topoisomerase II inhibitor; also inhibits protein kinase C (PKC) activity with an IC_{50} of 8.5 μM.</p> <p>Purity: 98.0%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 50 mg, 100 mg</p> 	<p>Mitoxantrone dihydrochloride (mitozantrone dihydrochloride) Cat. No.: HY-13502A</p> <p>Bioactivity: Mitoxantrone dihydrochloride is a topoisomerase II inhibitor; also inhibits protein kinase C (PKC) activity with an IC_{50} of 8.5 μM.</p> <p>Purity: 97.02%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 50 mg, 100 mg</p> 
<p>Phorbol 12-myristate 13-acetate (PMA) Cat. No.: HY-18739</p> <p>Bioactivity: Phorbol 12-myristate 13-acetate (PMA), a phorbol ester, is a commonly used PKC activator.</p> <p>Purity: 99.08%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg</p> 	<p>PKC-IN-1 Cat. No.: HY-16903</p> <p>Bioactivity: PKC-IN-1 is a potent, ATP-competitive and reversible inhibitor of conventional PKC enzymes with K_is of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC_{50}s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC μ ...</p> <p>Purity: 99.50%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>PKC-theta inhibitor Cat. No.: HY-112681</p> <p>Bioactivity: PKC-theta inhibitor is a selective PKC-θinhibitor, with an IC_{50} of 12 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 mg, 250 mg</p> 	<p>Ro 31-8220 (Bisindolylmaleimide IX) Cat. No.: HY-13866A</p> <p>Bioactivity: Ro 31-8220 is a potent PKC inhibitor, with IC_{50}s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCϵ and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC_{50}s, 3, 8, ...</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mg, 50 mg</p> 


Ro 31-8220 mesylate (Ro 31-8220 methanesulfonate; Bisindolylmaleimide IX mesylate) Cat. No.: HY-13866	
Bioactivity:	Ro 31-8220 mesylate is a potent PKC inhibitor, with IC₅₀s of 5, 24, 14, 27, 24 and 23 nM for PKC α , PKC β I, PKC β II, PKC γ , PKC ϵ and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3...
Purity:	99.28%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg
	


Rottlerin (Mallotoxin; NSC 56346; NSC 94525) Cat. No.: HY-18980	
Bioactivity:	Rottlerin is a specific PKC inhibitor, with IC₅₀ values for PKC δ of 3-6 μ M, PKC α,β,γ of 30-42 μ M, PKC ϵ,η,ζ of 80-100 μ M.
Purity:	>98%
Clinical Data:	No Development Reported
Size:	250 mg, 500 mg
	


Ruboxistaurin hydrochloride (LY 333531 hydrochloride) Cat. No.: HY-10195B	
Bioactivity:	Ruboxistaurin hydrochloride is a selective and ATP-competitive PKCβ inhibitor, with IC₅₀s of 4.7 and 5.9 nM for PKC β I and PKC β II, shows less potent inhibition on PKC η (IC₅₀ , 52 nM), PKC α (IC₅₀ , 360 nM), PKC γ (IC₅₀ , 300 nM), PKC δ (IC₅₀ , ...
Purity:	98.54%
Clinical Data:	Phase 3
Size:	10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
	


Sotrastaurin (AEB071) Cat. No.: HY-10343	
Bioactivity:	Sotrastaurin is a potent pan- PKC inhibitor, with K_s of 0.22 nM, 0.64nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKC θ , PKC β , PKC α , PKC η , PKC δ and PKC ϵ , respectively.
Purity:	99.70%
Clinical Data:	Phase 2
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
	

Staurosporine (Antibiotic AM-2282; STS; AM-2282) Cat. No.: HY-15141	
Bioactivity:	Staurosporine is a potent and non-selective inhibitor of protein kinases with IC₅₀s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC , PKA , c-Fgr , and Phosphorylase kinase respectively.
Purity:	99.98%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg
	

TAS-301 Cat. No.: HY-18965	
Bioactivity:	TAS-301 is an inhibitor of smooth muscle cell migration and proliferation, and inhibits PKC activation induced by PDGF.
Purity:	99.50%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
	

TPPB Cat. No.: HY-12359	
Bioactivity:	TPPB is a cell-permeable benzolactam-derived protein kinase C (PKC) activator with a K_i of 11.9 nM.
Purity:	99.81%
Clinical Data:	No Development Reported
Size:	1 mg, 5 mg
	

Valrubicin (AD-32) Cat. No.: HY-13772	
Bioactivity:	Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced PKC activation with IC₅₀s of 0.85 and 1.25 μ M, respectively, and has antitumor and anti-inflammatory activity.
Purity:	99.60%
Clinical Data:	Launched
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg
	


Verbascoside (Acteoside; Kusagin; TJC160) Cat. No.: HY-N0021	
Bioactivity:	Verbascoside is isolated from Lantana camara, acts as an ATP-competitive inhibitor of PKC , with an IC₅₀ of 25 μ M, and has antitumor, anti-inflammatory and antineuropathic pain activity.
Purity:	95.67%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg
	

β-Amyloid 1-40 Cat. No.: HY-P0265	
Bioactivity:	β -Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease. Sequence: Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val.
Purity:	95.09%
Clinical Data:	No Development Reported
Size:	500u g, 1 mg, 5 mg, 10 mg, 25 mg

Protein Arginine Deiminase

Peptidylarginine Deiminase

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)

citrullinate a number of other proteins, including p300, ING4, RPS2, lamin C, and nucleophosmin.

Protein arginine deiminases (PADs) is a unique family of enzymes that catalyzes the hydrolysis of peptidyl-arginine to form peptidyl-citrulline on histones, fibrinogen, and other biologically relevant proteins. In humans, the PAD family is composed of five, calcium dependent isozymes (PADs 1-4 and 6), which share roughly 50% sequence similarity. PADs are found in a myriad of cell and tissue types, including the epidermis and uterus (PAD1), skeletal muscle, brain, inflammatory cells, several cancer cell lines, and secretory glands (PAD2), hair follicles and keratinocytes (PAD3), granulocytes and several types of cancer (PAD4), and oocytes and embryos (PAD6). PAD4, the best characterized isozyme, has also been shown to

Protein Arginine Deiminase Inhibitors & Modulators

Cl-amidine


Cat. No.: HY-100574

Bioactivity: Cl-amidine is a **peptidylarginine deiminase (PAD)** inhibitor, with an **IC₅₀** 5.9 μ M for PAD4.

Purity: >98%

Clinical Data: No Development Reported

Size: 250 mg, 500 mg



GSK484

(GTP.L8577; AOB6992)


Cat. No.: HY-100514

Bioactivity: GSK484 is a peptidylarginine deiminase 4 (**PAD4**) inhibitor. GSK484 demonstrates high affinity binding to PAD4 with **IC₅₀**s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed.

Purity: 98.00%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



YW3-56


Cat. No.: HY-112903

Bioactivity: YW3-56 is a potent peptidylarginine deiminase (**PAD**) inhibitor, with an **IC₅₀** of 1-5 μ M for PAD4.

Purity: >98%


Clinical Data: No Development Reported

Size: 500 mg, 250 mg



Sirtuin

HDAC Inhibitor:
Vorinostat (SAHA)






HDAC (Histone deacetylase)

Sirtuin (Sir2 proteins) are a class of proteins that possess either mono-ADP-ribosyltransferase, or deacylase activity, including deacetylase, desuccinylase, demalonylase, demyristoylase and depalmitoylase activity. Sirtuins regulate important biological pathways in bacteria, archaea and eukaryotes. Sirtuins have been implicated in influencing a wide range of cellular processes like aging, transcription, apoptosis, inflammation and stress resistance, as well as energy efficiency and alertness during low-calorie situations. Sirtuins can also control circadian clocks and mitochondrial biogenesis.

Sirtuin Inhibitors & Modulators

<p>3-TYP</p> <p style="text-align: right;">Cat. No.: HY-108331</p> <p>Bioactivity: 3-TYP is a selective SIRT3 inhibitor, with an IC₅₀ of 16 nM, more potent over SIRT1 (IC₅₀=88 nM), SIRT2 (IC₅₀=92 nM).</p> <p>Purity: 99.87%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>AGK2</p> <p style="text-align: right;">Cat. No.: HY-100578</p> <p>Bioactivity: AGK2 is a selective SIRT2 inhibitor with IC₅₀ of 3.5 μM. AGK2 can also inhibit SIRT1 and SIRT3 with IC₅₀ of 30 and 91 μM, respectively.</p> <p>Purity: 98.66%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg</p> 
<p>AK-7</p> <p style="text-align: right;">Cat. No.: HY-16691</p> <p>Bioactivity: AK-7 is a selective cell- and brain-permeable SIRT2 inhibitor, with an IC₅₀ of 15.5 μM.</p> <p>Purity: 99.59%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 	<p>Cambinol</p> <p style="text-align: right;">Cat. No.: HY-100732</p> <p>Bioactivity: Cambinol is a SIRT1 and SIRT2 inhibitor with IC₅₀ values of 56 and 59 μM, respectively.</p> <p>Purity: 98.57%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>CAY10602</p> <p style="text-align: right;">Cat. No.: HY-104073</p> <p>Bioactivity: CAY10602 is a SIRT1 activator.</p> <p>Purity: 98.56%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>EX-527 (Selisistat)</p> <p style="text-align: right;">Cat. No.: HY-15452</p> <p>Bioactivity: EX-527 is a potent and selective SIRT1 inhibitor with IC₅₀ of 98 nM.</p> <p>Purity: 99.82%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg</p> 
<p>EX-527 R-enantiomer (Selisistat R-enantiomer)</p> <p style="text-align: right;">Cat. No.: HY-15452B</p> <p>Bioactivity: EX-527 R-enantiomer is much less active R-enantiomer of EX-527, with an IC₅₀ of > 100 μM for SIRT1.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg</p> 	<p>EX-527 S-enantiomer (Selisistat S-enantiomer)</p> <p style="text-align: right;">Cat. No.: HY-15452A</p> <p>Bioactivity: EX-527 S-enantiomer is the S-enantiomer of EX-527, with an IC₅₀ of 123 nM for SIRT1. EX-527 S-enantiomer is much more potent than EX-527 R-enantiomer.</p> <p>Purity: 98.29%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg</p> 
<p>Fisetin</p> <p style="text-align: right;">Cat. No.: HY-N0182</p> <p>Bioactivity: Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.</p> <p>Purity: 98.0%</p> <p>Clinical Data: Phase 2</p> <p>Size: 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g</p> 	<p>Ginkgolide C (BN-52022; Ginkgolide-C)</p> <p style="text-align: right;">Cat. No.: HY-N0785</p> <p>Bioactivity: Ginkgolide C is a flavone isolated from Ginkgo biloba leaves, possessing multiple biological functions, such as decreasing platelet aggregation and ameliorating Alzheimer disease.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 

<p>Inauhzin (INZ) Cat. No.: HY-15869</p> <p>Bioactivity: Inauhzin is a dual Sirt1/IMPDH2 inhibitor, and acts as an activator p53, used in the research of cancer.</p> <p>Purity: 98.91% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>MC3482 Cat. No.: HY-112587</p> <p>Bioactivity: MC3482 is a specific sirtuin5 (SIRT5) inhibitor.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 500 mg, 250 mg</p> 
<p>Nicotinamide (Niacinamide; Nicotinic acid amide; Vitamin B3) Cat. No.: HY-B0150</p> <p>Bioactivity: Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1.</p> <p>Purity: 98.0% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 1 g, 5 g</p> 	<p>OSS_128167 Cat. No.: HY-107454</p> <p>Bioactivity: OSS_128167 is a selective SIRT6 inhibitor with IC₅₀s of 89, 1578 and 751 μM for SIRT6, SIRT1 and SIRT2, respectively.</p> <p>Purity: 98.22% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Salermide Cat. No.: HY-101073</p> <p>Bioactivity: Salermide is an inhibitor of Sirt1 and Sirt2; can cause strong cancer-specific apoptotic cell death.</p> <p>Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>SIRT-IN-1 Cat. No.: HY-16615</p> <p>Bioactivity: SIRT-IN-1 is a potent inhibitor of SIRT1/2/3, with IC₅₀s of 15, 10, 33 μM, respectively.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p> 
<p>SIRT-IN-2 Cat. No.: HY-16616</p> <p>Bioactivity: SIRT-IN-2 is a potent inhibitor of SIRT1/2/3, with IC₅₀s of 4, 4, 7 μM, respectively.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p> 	<p>SIRT2 Inhibitor II (AK-1) Cat. No.: HY-101465</p> <p>Bioactivity: AK-1 is a potent, specific and cell-permeable SIRT2 inhibitor.</p> <p>Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg</p> 
<p>SIRT5 inhibitor Cat. No.: HY-112634</p> <p>Bioactivity: SIRT5 inhibitor is a potent Human Sirtuin 5 deacetylase inhibitor, with an IC₅₀ of 0.11 μM.</p> <p>Purity: 99.36% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Sirtinol Cat. No.: HY-13515</p> <p>Bioactivity: Sirtinol is a sirtuin inhibitor, with IC₅₀s of 48 μM, 57.7 μM and 131 μM for γSir2, hSIRT2 and hSIRT2, respectively.</p> <p>Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 

<p>Sirtuin modulator 1</p> <p style="text-align: right;">Cat. No.: HY-19758A</p> <p>Bioactivity: Sirtuin modulator 1 is a modulator of SIRT1, a homolog of SIRT3, with $EC_{1.5}$ of $< 1 \mu\text{M}$, extracted from patent WO 2010071853 A1, Compound No.4.</p> <p>Purity: 99.44%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>SRT 1720</p> <p style="text-align: right;">Cat. No.: HY-10532</p> <p>Bioactivity: SRT 1720 is a selective activator of human SIRT1 with an $EC_{1.5}$ of $0.16 \mu\text{M}$, and shows less potent activities against SIRT2 and SIRT3 with $EC_{1.5}$s of $37 \mu\text{M}$ and $> 300 \mu\text{M}$, respectively.</p> <p>Purity: $> 98\%$</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>SRT 1720 Hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-15145</p> <p>Bioactivity: SRT 1720 Hydrochloride is a selective activator of SIRT1 with an $EC_{1.5}$ of $0.16 \mu\text{M}$, and shows less potent activities on SIRT2 and SIRT3 with $EC_{1.5}$s of $37 \mu\text{M}$ and $300 \mu\text{M}$, respectively.</p> <p>Purity: 99.92%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>SRT 2104</p> <p style="text-align: right;">Cat. No.: HY-15262</p> <p>Bioactivity: SRT 2104 is a brain-permeable activator of SIRT1, used for the research of type 2 diabetes mellitus and Huntington's disease.</p> <p>Purity: 98.51%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 50 mg</p> 
<p>Tenovin 6 Hydrochloride (Tenovin 2)</p> <p style="text-align: right;">Cat. No.: HY-15510B</p> <p>Bioactivity: Tenovin-6 Hydrochloride is a water soluble inhibitor of SIRT1 and SIRT2, slightly inhibits HDAC8, and is also a potent activator of p53, with IC_{50}s of $21 \mu\text{M}$, $10 \mu\text{M}$, $67 \mu\text{M}$ for SirT1, SirT2, and SirT3, respectively.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Tenovin-1</p> <p style="text-align: right;">Cat. No.: HY-13423</p> <p>Bioactivity: Tenovin-1 is an inhibitor of sirtuin 1 and sirtuin 2, an activator of p53 and may have potential in the management of cancer.</p> <p>Purity: 99.39%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 
<p>Tenovin-6</p> <p style="text-align: right;">Cat. No.: HY-15510</p> <p>Bioactivity: Tenovin-6 is a water soluble inhibitor of SIRT1 and SIRT2, slightly inhibits HDAC8, and is also a potent activator of p53, with IC_{50}s of $21 \mu\text{M}$, $10 \mu\text{M}$, and $67 \mu\text{M}$ for SirT1, SirT2, and SirT3, respectively.</p> <p>Purity: 98.24%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Thiomiristoyl</p> <p style="text-align: right;">Cat. No.: HY-101278</p> <p>Bioactivity: Thiomiristoyl is a potent and specific SIRT2 inhibitor with an IC_{50} of 28 nM.</p> <p>Purity: 98.84%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 